Total Allowable Error Table
Total Allowable Error Table (Updated junio 2024)
Click here to view the table with target values prior to junio 2024.
| Analyte | Fluid | Method | Target Value | Source |
|---|---|---|---|---|
| 17-Hydroxyprogesterone | Serum | ±2,0 nmol/L or 20% if > 10,0 nmol/L | 5 RCPA | |
| 3-Methoxytyramine (3MT) | Urine | ±15 nmol/L or ± 15% if > 100 nmol/L | 5 RCPA | |
| 4-hydroxy-3-methoxy-mandelate, (HMMA) | Urine | ±6 μmol/L or 15% if > 40 μmol/L | 5 RCPA | |
| 5HIAA | Urine | ±8 μmol/L or 20% if > 40 μmol/L | 5 RCPA | |
| a1-Antitrypsin (α1AT) | Serum | ±0,10 g/L or 20% if > 0,5 g/L | 5 RCPA | |
| Acetaminophen (Paracetamol) | Serum | ±15% or 3 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Acetaminophen (Paracetamol) | Serum | ±15% or 2,5 µg/mL (greater) | 4 AAB | |
| Acetaminophen (Paracetamol) | Serum | ±3,0 mg/L or 10% if > 30,0 mg/L | 5 RCPA | |
| Activated Clotting Time (ACT) | Plasma | ±20% | 2 WSLH | |
| Adrenaline | Urine | ±30 nmol/L or 30% if > 100 nmol/L | 5 RCPA | |
| Adrenocorticotropic Hormone (ACTH) | Serum | ±2,0 pmol/L or 10% if > 20 pmol/L | 5 RCPA | |
| Alanine Aminotransferase (ALT) | Serum | ±15% or 6 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Alanine Aminotransferase (ALT) | Serum | ±20% | 4 AAB | |
| Alanine Aminotransferase (ALT) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
| Albumin | Serum | ±8% | 1 CLIA, 2 WSLH, 3 CAP | |
| Albumin | Body Fluids | ±10% | 2 WSLH | |
| Albumin | Serum | ±10% | 4 AAB | |
| Albumin | Serum, Body Fluids | ±2,0 g/L or 6% if > 33 g/L | 5 RCPA | |
| Albumin | CSF | ±0,02 g/L or 20% if > 0,1 g/L | 5 RCPA | |
| Albumin | Urine | ±4,0 mg/L or 20% if > 20,0 mg/L | 5 RCPA | |
| Alcohol (ETOH) | Serum | ±20% | 1 CLIA, 2 WSLH | |
| Alcohol (ETOH) | Serum | ±25% | 4 AAB | |
| Alcohol (ETOH) | Serum | ±2,0 mmol/L or 10% if > 20 mmol/L | 5 RCPA | |
| Aldosterone | Serum | ±24 pmol/L or 15% if > 160 pmol/L | 5 RCPA | |
| Alkaline Phosphatase (ALP) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Alkaline Phosphatase (ALP) | Serum | ±30% | 4 AAB | |
| Alkaline Phosphatase (ALP) | Serum | ±15 U/L or 12% if > 125 U/L | 5 RCPA | |
| Alpha 1 Antitrypsin | Serum | ±20% | 1 CLIA | |
| Alpha-fetoprotein (AFP) | Serum | ±20% | 1 CLIA, 2 WSLH | |
| Alpha-fetoprotein (AFP) | Serum | ±2 kIU/L or 12% if > 17 kIU/L | 5 RCPA | |
| Aluminum | Serum | ±0,08 μmol/L or 20% if > 0,40 μmol/L | 5 RCPA | |
| Amikacin | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Amikacin | Serum | ±2 mg/L or 10% if > 19,9 mg/L | 5 RCPA | |
| Aminolaevulinic Acid (ALA) | Urine | ±8 μmol/L or 25% if > 32 μmol/L | 5 RCPA | |
| Amiodarone | Serum | ±0,1 mg/L or 10% if > 1,3 mg/L | 5 RCPA | |
| Amitriptyline | Serum | ±3,0 μg/L or 10% if > 28,0 μg/L | 5 RCPA | |
| Ammonia | Serum | ±5% or 10 µmol/L (greater) | 4 AAB | |
| Ammonia | Serum | ±5 μmol/L or 10% if > 50 μmol/L | 5 RCPA | |
| Amylase | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Amylase | Serum | ±30% | 4 AAB | |
| Amylase | Body Fluids, Urine | ±30% | 2 WSLH | |
| Amylase | Serum | ±10 U/L or 10% if > 100 U/L | 5 RCPA | |
| Amylase | Body Fluids | ±20 U/L or 20% if > 100 U/L | 5 RCPA | |
| Androstenedione | Serum | ±1,5 nmol/L or 15% if > 10 nmol/L | 5 RCPA | |
| Angiotensin Converting Enzyme (ACE) | Serum | ±1,0 or 10% if > 10,0 U/L | 5 RCPA | |
| Antinuclear antibody (ANA) | Serum | ±2 dilutions or positive or negative | 1 CLIA | |
| Antistreptolysin O (ASO) | Serum | ±2 dilutions or positive or negative | 1 CLIA | |
| Antithrombin, Functional (AT) | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Anti HIV (Human Immunodeficiency virus) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA | |
| Anti Xa | Plasma | ±25 ng/mL or 25% if > 100 ng/mL | 5 RCPA | |
| Apolipoprotein A1 | Serum | ±0,2 g/L or 10% if > 2,0 g/L | 5 RCPA | |
| Apolipoprotein B | Serum | ±0,2 g/L or 10% if > 2,0 g/L | 5 RCPA | |
| Arsenic, Total | Urine | ±50 nmol/L or 10% if > 500 nmol/L | 5 RCPA | |
| Arsenic, Total | WB | ±10 nmol/L or 10% if > 100 nmol/L | 5 RCPA | |
| Aspartate Aminotransferase (AST) | Serum | ±15% or 6 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Aspartate Aminotransferase (AST) | Serum | ±20% | 4 AAB | |
| Aspartate Aminotransferase (AST) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
| Basophile, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Beta-2 microglobulin (B2M) | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
| Beta Carotene | Serum | ±0,4 μmol/L or 25% if > 2,0 μmol/L | 5 RCPA | |
| Bile Acids, Total | Serum | ±4 μmol/L or 10% if > 40 μmol/L | 5 RCPA | |
| Bilirubin, Direct or Conjugated (DBIL) | Serum | ±0,4 mg/dL or 20% (greater) | 2 WSLH, 3 CAP | |
| Bilirubin, Direct or Conjugated (DBIL) | Serum | ±3 μmol/L or 20% if > 15 μmol/L | 5 RCPA | |
| Bilirubin, Neonatal (TBIL) | Serum | ±20% or 0,4 mg/dL (greater) | 4 AAB | |
| Bilirubin, Neonatal (TBIL) | Serum | ±8 μmol/L or 10% if > 80 μmol/L | 5 RCPA | |
| Bilirubin, Total | Serum | ±20% or 0,4 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Bilirubin, Total | Serum | ±3 μmol/L or 12% if > 25 μmol/L | 5 RCPA | |
| Bilirubin, Total | CSF | ±0,12 μmol/L or 20% if > 0,6 μmol/L | 5 RCPA | |
| B-natriuretic Peptide (BNP) | Serum | ±30% | 1 CLIA, 2 WSLH | |
| B-natriuretic Peptide (BNP) | Serum | ±2 SD or 25% (greater) | 4 AAB | |
| B-natriuretic Peptide (BNP) | Serum | ±20 ng/L or 20% if > 100 ng/L | 5 RCPA | |
| B-natriuretic Peptide, Pro (proBNP) | Serum | ±30% | 2 WSLH | |
| B-natriuretic Peptide, Pro (proBNP) | Serum | ±25% | 4 AAB | |
| B-natriuretic Peptide, Pro (proBNP) | Serum | ±25 ng/L or 20% if > 125 ng/L | 5 RCPA | |
| C Peptide | Serum | ±0,15 nmol/L or 12% if > 1,25 nmol/L | 5 RCPA | |
| C1 Inhibitor, Esterase (C1inh) | Serum | ±0,03 g/L or 15% if > ±0,2 g/L | 5 RCPA | |
| Cadmium | Urine, WB | ±1 mg/dL or 15% | 2 WSLH | |
| Cadmium | Urine, WB | ±3 nmol/L or 15% if > 20 nmol/L | 5 RCPA | |
| Caffeine | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Calcitonin | Serum | ±2 ng/L or 10% if > 20 ng/L | 5 RCPA | |
| Calcium - Total | Serum | ±1,0 mg/dL | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Calcium - Total | Urine | ±10% or 1 mg/dL | 2 WSLH | |
| Calcium - Total | Serum | ±0,1 mmol/L or 4% if > 2,5 mmol/L | 5 RCPA | |
| Calcium - Total | Urine | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
| Calcium, Ionized | Serum | ±0,13 mmol/L | 2 WSLH | |
| Calcium, Ionized | Serum | ±0,04 mmol/L or 4% if > 1,00 mmol/L | 5 RCPA | |
| Cancer Antigen (CA) 125 | Serum | ±6 kU/L or 12% if > 50 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 15-3 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Cancer Antigen (CA) 15-3 | Serum | ±3 kU/L or 10% if > 30 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 19-9 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Cancer Antigen (CA) 19-9 | Serum | ±6 kU/L or 15% if > 40 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 19-9 | Body Fluids | ±12 kU/L or 30% if > 40 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 27,29 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Carbamazepine | Serum | ±20% or 1,0 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Carbamazepine | Serum | ±25% | 4 AAB | |
| Carbamazepine | Serum | ±0,5 mg/L or 10% if > 4,7 mg/L | 5 RCPA | |
| Carbamazepine, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Carcinoembryonic Antigen (CEA) | Serum | ±15% or 1 ng/mL (greater) | 1 CLIA, 2 WSLH | |
| Carcinoembryonic Antigen (CEA) | Serum | ±1,2 ng/mL or 20% | 4 AAB | |
| Carcinoembryonic Antigen (CEA) | Serum | ±0,6 μg/L or 12% if > 5 μg/L | 5 RCPA | |
| Carcinoembryonic Antigen (CEA) | Body Fluids | ±1,2 μg/L or 24% if > 5,0 μg/L | 5 RCPA | |
| Carotenoids, Total | Serum | ±0,8 μmol/L or 25% if > 4,0 μmol/L | 5 RCPA | |
| CD3+ Alpha-beta% | WB | ±4,5% to 15% if > 30% | 5 RCPA | |
| CD3+% | WB | ±1,5% or 5% if > 30% | 5 RCPA | |
| CD3x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD4x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD3+/CD4+% | WB | ±3% or 7,5% if > 40% | 5 RCPA | |
| CD3+/CD8+% | WB | ±1,5% or 10% if > 15% | 5 RCPA | |
| CD3-CD16+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD3-CD56+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD3-CD16+56+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD8x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD19+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD19x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD34+, % | WB | ±0,05% or 25% if > 0,3% | 5 RCPA | |
| CD34+, Total | WB | ±5 μL or 25% if > 20 μL | 5 RCPA | |
| Ceruloplasmin | Serum | ±0,03 g/L or 15% if > 0,2 g/L | 5 RCPA | |
| Chloride | Serum | ±5% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Chloride | Urine | ±10% | 2 WSLH | |
| Chloride | Serum | ±3 mmol/L or 3% if > 100 mmol/L | 5 RCPA | |
| Chloride | Sweat | ±2,0 mmol/L or 5% if > 40 mmol/L | 5 RCPA | |
| Chloride | Urine | ±4,0 mmol/L or 10% if > 40 mmol/L | 5 RCPA | |
| Cholesterol, HDL | Serum | ±20% or 6 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Cholesterol, HDL | Serum | ±30% | 4 AAB | |
| Cholesterol, HDL | Serum | ±0,1 mmol/L or 12% if > 0,8 mmol/L | 5 RCPA | |
| Cholesterol, LDL | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Cholesterol, LDL | Serum | ±30% | 4 AAB | |
| Cholesterol, LDL | Serum | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
| Cholesterol, Total | Serum | ±10% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Cholesterol, Total | Body Fluids | ±10% | 2 WSLH | |
| Cholesterol, Total | Serum | ±0,3 mmol/L or 6% if > 5,0 mmol/L | 5 RCPA | |
| Cholesterol, Total | Body Fluids | ±0,3 mmol/L or 12% if > 2,5 mmol/L | 5 RCPA | |
| Cholinesterase | Serum | ±500 U/L or 10% if > 5000 U/L | 5 RCPA | |
| Chromium | Serum, Urine, WB | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
| Clozapine | Serum | ±12 μg/L or 12% if > 100 μg/L | 5 RCPA | |
| CO2, Carbon Dioxide (Bicarbonate) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| CO2, Carbon Dioxide (Bicarbonate) | Serum | ±2,0 mmol/L or 10% if > 20,0 mmol/L | 5 RCPA | |
| Cobalt | Plasma | ±1 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Cobalt | Urine | ±2 nmol/L or 10% if > 20 nmol/L | 5 RCPA | |
| Cobalt | WB | ±2 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Compatibility testing | Serum | 100% accuracy | 1 CLIA | |
| Complement C3 | Serum | ±15% | 1 CLIA | |
| Complement C3 | Serum | ±0,10 g/L or 10% if > 1,0 g/L | 5 RCPA | |
| Complement C4 | Serum | ±20% or 5 mg/dL (greater) | 1 CLIA | |
| Complement C4 | Serum | 0,02 g/L or 10% if > 0,2 g/L | 5 RCPA | |
| Conductivity | Sweat | ±2 mmol/L or 5% if > 50 mmol/L | 5 RCPA | |
| Copper | Serum | ±1,6 μmol/L or 8% if > 20,0 μmol/L | 5 RCPA | |
| Copper | Urine | ±0,05 μmol/L or 10% if > 0,50 μmol/L | 5 RCPA | |
| Cortisol | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Cortisol | Serum | ±25% | 4 AAB | |
| Cortisol | Serum | ±15 nmol/L or 15% if > 100 nmol/L | 5 RCPA | |
| Cortisol | Urine | ±30 nmol/L or 15% if > 200 nmol/L | 5 RCPA | |
| C-Reactive protein (CRP) | Serum | ±30% or 2 SD (greater) | 4 AAB | |
| C-Reactive protein (CRP) | Serum | ±0,8 mg/L or 20% if > 4,0 mg/L | 5 RCPA | |
| C-Reactive protein (CRP), High Sensitivity | Serum | ±30% or 1 mg/L (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
| C-Reactive protein (CRP), High Sensitivity | Serum | ±0,6 mg/L or 20% if > 3,0 mg/L | 5 RCPA | |
| Creatine Kinase (CK) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Creatine Kinase (CK) | Serum | ±30% | 4 AAB | |
| Creatine Kinase (CK) | Serum | ±15 U/L or 12% if > 125 U/L | 5 RCPA | |
| Creatine Kinase Isoenzyme (CKMB) | Serum | ±25% or 3 ng/mL (greater) or MB elevated (presence or absence) | 1 CLIA, 2 WSLH | |
| Creatine Kinase Isoenzyme (CKMB) | Serum | ±3 U/L or 3 μg/L or 20% if > 15 U/L or 15 μg/L | 5 RCPA | |
| Creatinine | Serum | ±10% or 0,2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Creatinine | Body Fluids, Urine | ±17% or 0,3 mg/dL | 2 WSLH | |
| Creatinine | Serum | ±0,3 mg/dL or 15% (greater) | 4 AAB | |
| Creatinine | Serum, Urine | ±17% | 4 AAB | |
| Creatinine | Serum | ±8,0 μmol/L or 8% if > 100 μmol/L | 5 RCPA | |
| Creatinine | Body Fluids | ±16,0 μmol/L or 16% if > 100 μmol/L | 5 RCPA | |
| Creatinine | Urine | ±0,5 mmol/L or 10% if > 5,0 mmol/L | 5 RCPA | |
| Cyclosporine | Serum | ±10 μg/L or 10% if > 100 μg/L | 5 RCPA | |
| d-Dimer | Plasma | ±15% | 2 WSLH | |
| d-Dimer | Plasma | ±2 SD or 30% (greater) | 4 AAB | |
| d-Dimer | Plasma | automated DD | ±0,25 DD mg/L or 50% if > 0,5 DD mg/L | 5 RCPA |
| d-Dimer | Plasma | automated FEU | ±0,5 FEU mg/L or 50% if > 1,0 FEU mg/L | 5 RCPA |
| DHEA Sulfate | Serum | ±30% or 2 SD (greater) | 4 AAB | |
| DHEA Sulfate | Serum | ±1,2 μmol/L or 12% if > 10 μmol/L | 5 RCPA | |
| Digoxin | Serum | ±15% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Digoxin | Serum | ±0,2 ng/dL or 20% (greater) | 4 AAB | |
| Digoxin | Serum | ±0,2 μg/L or 10% if > 1,6 μg/L | 5 RCPA | |
| Digoxin, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Dihydropyrimidine dehydrogenase (DPYD) Free | Urine | ±15 nmol/L or 15% if > 80 nmol/L | 5 RCPA | |
| Direct Thrombin Inhibitor, (DTI) | Plasma | ±25 ng/mL or 25% if >100 ng/mL | 5 RCPA | |
| Disopyramide | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Dopamine | Urine | ±0,2 μmol/L or 10% if > 2,0 μmol/L | 5 RCPA | |
| Eosinophils, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Erythrocyte Sedimentation Rate (ESR) | WB | ±3,0 mm/hr or 30% if > 10 mm/hr | 5 RCPA | |
| Estradiol | Serum | ±30% | 1 CLIA, 2 WSLH, 4 AAB | |
| Estradiol (Oestradiol) | Serum | ±25 pmol/L or 25% if > 100 pmol/L | 5 RCPA | |
| Estriol, Unconjugated (Oestriol) | Serum | ±0,9 nmol/L or 15% if > 6,0 nmol/L | 5 RCPA | |
| Ethosuximide | Serum | ±20% | 3 CAP | |
| Factor II, V, VII, IX, X, XI, XII | Plasma | ±3 IU/dL or 30% if > 10 IU/dL | 5 RCPA | |
| Factor VIII:C | Plasma | ±3% or 30% if > 10% | 5 RCPA | |
| Fecal Occult Blood (FOBT) | Stool | ±15 ng/mL or 15% if > 100 ng/mL | 5 RCPA | |
| Ferritin | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Ferritin | Serum | ±4,0 μg/L or 15% if 27,0 μg/L | 5 RCPA | |
| Fibrinogen | Plasma | ±20% | 1 CLIA, 2 WSLH, 4 AAB | |
| Fibrinogen | Plasma | ±0,2 g/L or 25% if > 1,0 g/L | 5 RCPA | |
| Fluconazole | Serum | ±2,0 mg/L or 10% if > 20 mg/L | 5 RCPA | |
| Flucytosine | Serum | ±10 mg/L or 10% if > 100 mg/L | 5 RCPA | |
| Folate | Serum | ±30% or 1 ng/mL (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
| Folate | Serum | ±1,5 nmol/L or 25% if > 6,0 nmol/L | 5 RCPA | |
| Folate, RBC | WB | ±80 nmol/L or 20% if > 400 nmol/L | 5 RCPA | |
| Follicle Stimulating Hormone (FSH) | Serum | ±18% or 2 IU/L (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
| Follicle Stimulating Hormone (FSH) | Serum | ±1,0 IU/L or 10% if > 10,0 IU/L | 5 RCPA | |
| Fractional Carboxyhemoglobin | WB | ±1% or 20% if > 5% | 5 RCPA | |
| Fractional Methemoglobin | WB | ±2% or 10% if > 20% | 5 RCPA | |
| Fractional Oxyhemoglobin | WB | ±3% or 4% if > 75% | 5 RCPA | |
| Fructosamine | Serum | ±15 μmol/L or 6% if > 250 μmol/L | 5 RCPA | |
| Gamma glutamyl transferase (GGT) | Serum | ±15% or 5 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Gamma glutamyl transferase (GGT) | Serum | ±2 SD or 15% (greater) | 4 AAB | |
| Gamma glutamyl transferase (GGT) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
| Gastrin | Serum | ±10 pmol/L or 10% if > 100 pmol/L | 5 RCPA | |
| Gentamicin | Serum | ±25% | 1 CLIA, 2 WSLH, 3 CAP | |
| Gentamicin | Serum | ±25% or 1,0 µg/mL (greater) | 4 AAB | |
| Gentamicin | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
| Glucose | Serum | ±8% or 6 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Glucose | Body Fluids, CSF, Urine | ±10% | 2 WSLH | |
| Glucose | WB | ±20% or 15 mg/dL | 2 WSLH | |
| Glucose | Serum | ±6 mg/dL or 10% (greater) | 4 AAB | |
| Glucose | WB | ±6 mg/dL or 20% (greater) | 4 AAB | |
| Glucose | Serum, Body Fluids | ±0,4 mmol/L or 8% if > 5,0 mmol/L | 5 RCPA | |
| Glucose | CSF | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
| Glucose | Urine | ±1,0 mmol/L or 10% if > 10,0 mmol/L | 5 RCPA | |
| Glucose-6-phosphate-1-dehydrogenase (G6PD) | WB | ±3,0 U/g Hb or 30% if > 10 U/g Hb | 5 RCPA | |
| Growth Hormone | Serum | ±1,0 mU/L or 15% if > 7,0 mU/L | 5 RCPA | |
| Haptoglobin | Serum | ±0,1 g/L or 10% if > 0,8 g/L | 5 RCPA | |
| Hematocrit | WB | ±4% | 1 CLIA, 2 WSLH | |
| Hematocrit | WB | ±6 mg/dL or 20% (greater) | 4 AAB | |
| Hematocrit | WB | ±4% or 20% if > 20% | 5 RCPA | |
| Hemoglobin | WB | ±4% | 1 CLIA, 2 WSLH | |
| Hemoglobin | WB | ±7% | 4 AAB | |
| Hemoglobin | WB | ±5 g/L or 5% if > 100 g/L | 5 RCPA | |
| Hemoglobin A1c (Glycohemoglobin) | WB | ±8% | 1 CLIA, 2 WSLH | |
| Hemoglobin A1c (Glycohemoglobin) | WB | ±5% | 4 AAB | |
| Hemoglobin A1c (Glycohemoglobin) | WB | IFCC | ±4 mmol/mol or 8% if > 45 mmol/mol | 5 RCPA |
| Hemoglobin A1c (Glycohemoglobin) | WB | NGSP | ±0,4% or 6% if > 6,7% | 5 RCPA |
| Hemoglobin, A2 | WB | ±0,3% or 10% if > 2,0 | 5 RCPA | |
| Hemoglobin, F | WB | ±0,5% or 30% if > 1,5% | 5 RCPA | |
| Hemoglobin, Variant | WB | ±4% or 20% if > 20,0% | 5 RCPA | |
| Hemolysis, Serum Index | Serum | ±8 mg/dL or 10% if > 80 mg/dL | 5 RCPA | |
| Hepatitis (Anti-HBc, HBsAg, HBeAg, Anti-HCV) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA, 2 WSLH | |
| Hepatitis, Surface Antibody (Anti-HBs) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA, 2 WSLH | |
| Homocysteine | Serum | ±30% | 4 AAB | |
| Homocysteine | Serum | ±1,5 μmol/L or 10% if > 15 μmol/L | 5 RCPA | |
| Homovanillic Acid (HVA) | Urine | ±6 μmol/L or 15% if > 40 μmol/L | 5 RCPA | |
| Human Chorionic Gonadotropin (HCG) | Serum | ±18% or 3 mIU/mL (greater) or positive or negative | 1 CLIA, 2 WSLH, 3 CAP | |
| Human Chorionic Gonadotropin (HCG) | Serum | ±18% or 2 SD (greater) | 4 AAB | |
| Human Chorionic Gonadotropin (HCG) | Serum | ±1,0 IU/L or 10% if > 10,0 IU/L | 5 RCPA | |
| Human Chorionic Gonadotropin (HCG) | Urine | ±5,0 IU/L or 10% if > 50 IU/L | 5 RCPA | |
| Hydroxyitraconazole | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
| Icterus, Serum Index | Serum | ±6,0 μmol/L or 25% if > 25,0 μmol/L | 5 RCPA | |
| IgA | Serum | ±20% | 1 CLIA | |
| IgA | Serum | ±0,06 g/L or 10% if > 0,6 g/L | 5 RCPA | |
| IgD | Serum | ±0,2 g/L or 20% if > 1,0 g/L | 5 RCPA | |
| IgE | Serum | ±20% | 1 CLIA | |
| IgE | Serum | ±20 kU/L or 20% if > 100 kU/L | 5 RCPA | |
| IgG | Serum | ±20% | 1 CLIA | |
| IgG | Serum | ±25% | 4 AAB | |
| IgG | Serum | ±0,6 g/L or 10% if > 6 g/L | 5 RCPA | |
| IgG | CSF | ±0,02 g/L or 20% if > 0,1 g/L | 5 RCPA | |
| IgM | Serum | ±20% | 1 CLIA | |
| IgM | Serum | ±0,08 g/L or 15% If > 0,5 g/L | 5 RCPA | |
| Immature granulocytes (IG's) | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Infectious mononucleosis | Serum | ±2 dilutions or positive or negative | 1 CLIA, 2 WSLH | |
| INR | Plasma | ±15% | 1 CLIA, 2 WSLH, 4 AAB | |
| INR | Plasma | ±0,3 ratio or 15% if > 2,0 ratio | 5 RCPA | |
| Insulin | Serum | ±6 mU/L or 12% if > 5 mU/L | 5 RCPA | |
| Insulin-like Growth Factor (IGF-1) | Serum | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
| Insulin-like Growth Factor Binding Protein (IGFBP-3) | Serum | ±15 nmol/L or 15% if > 100 nmol/L | 5 RCPA | |
| Iodine | Urine | ±80 nmol/L or 10% if > 800 nmol/L | 5 RCPA | |
| Iron (Fe) | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
| Iron (Fe) | Serum | ±20% | 4 AAB | |
| Iron (Fe) | Serum, Urine | ±3,0 μmol/L or 12% if > 25,0 μmol/L | 5 RCPA | |
| Iron Binding Capacity, Total (IBC) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Iron Binding Capacity, Total (IBC) | Serum, Urine | ±20% | 4 AAB | |
| Iron Binding Capacity, Total (IBC) | Serum | ±4 μmol/L or 8% if > 50,0 μmol/L | 5 RCPA | |
| Iron Binding Capacity, Unsaturated (UIBC) | Serum | ±20% | 2 WSLH | |
| Itraconazole | Serum | ±0,1 mg/L or 10% if > 1,0 mg/L | 5 RCPA | |
| Lactate | Serum | ±0,2 mmol/L | 2 WSLH | |
| Lactate | CSF | ±10% | 2 WSLH | |
| Lactate | Serum | ±0,4 mmol/L or 3 SD (greater) | 3 CAP, 4 AAB | |
| Lactate | Serum | ±0,5 mmol/L or 12% if > 4,0 mmol/L | 5 RCPA | |
| Lactate | CSF | ±0,3 mmol/L or 10% if > 3,0 mmol/L | 5 RCPA | |
| Lactate | Body Fluids | ±1,0 mmol/L or 25% if > 4,0 mmol/L | 5 RCPA | |
| Lactate Dehydrogenase (LD, LDH) | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
| Lactate Dehydrogenase (LD, LDH) | Body Fluids | ±20% | 2 WSLH | |
| Lactate Dehydrogenase (LD, LDH) | Serum | ±20% | 4 AAB | |
| Lactate Dehydrogenase (LD, LDH) | Serum, Body Fluids | ±20 U/L or 8% if > 250 U/L | 5 RCPA | |
| Lead (Pb) | WB | ±10% or 2 µg/dL (greater) | 1 CLIA, 2 WSLH | |
| Lead (Pb) | WB | ±4 µg/dL or 10% (greater) | 4 AAB | |
| Lead (Pb) | Urine | ±50 nmol/L or 10% if > 500 nmol/L | 5 RCPA | |
| Lead (Pb) | WB | ±0,05 μmol/L or 10% if > 0,50 μmol/L | 5 RCPA | |
| Lidocaine | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Lipase | Serum | ±30% | 2 WSLH, 3 CAP, 4 AAB | |
| Lipase | Serum | ±12 U/L or 20% if > 60 U/L | 5 RCPA | |
| Lipase | Body Fluids | ±24 U/L or 40% if > 60 U/L | 5 RCPA | |
| Lipemia, Serum Index | Serum | ±26 mg/dL or 10% if > 263 mg/dL | 5 RCPA | |
| Lipoprotein (a) | Serum | ±0,06 g/L or 20% if > 0,3 g/L | 5 RCPA | |
| Lithium | Serum | ±15% or 0,3 mmol/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Lithium | Serum | ±0,3 mmol/L or 20% (greater) | 4 AAB | |
| Lithium | Serum | ±0,2 mmol/L or 10% if > 2,0 mmol/L | 5 RCPA | |
| Luteinizing Hormone (LH) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Luteinizing Hormone (LH) | Serum | ±1,5 IU/L or 15% if > 10,0 IU/L | 5 RCPA | |
| Lymphocytes, count | WB | ±2% or 20% if > 10% | 5 RCPA | |
| Magnesium | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
| Magnesium | Urine | ±25% | 2 WSLH | |
| Magnesium | Serum | ±25% | 4 AAB | |
| Magnesium | Serum, WB | ±0,1 mmol/L or 8% if > 1,25 mmol/L | 5 RCPA | |
| Magnesium | Urine | ±0,3 mmol/L or 15% if > 2,0 mmol/L | 5 RCPA | |
| Magnesium | Urine | ±0,1 mmol/L or 8% if > 1,25 mmol/L | 5 RCPA | |
| Manganese | Serum | ±0,1 nmol/L or 8% if | 5 RCPA | |
| Manganese | Urine | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
| Manganese | WB | ±30 nmol/L or 12% if > 250 nmol/L | 5 RCPA | |
| Mean corpuscular hemoglobin (MCH) | WB | ±2 pg or 10% if > 20 pg | 5 RCPA | |
| Mean corpuscular hemoglobin concentration (MCHC) | WB | ±30 g/L or 10% if > than 300 g/L | 5 RCPA | |
| Mean corpuscular volume (MCV) | WB | ±5 fL or 10% if > 50 fL | 5 RCPA | |
| Mean platelet volume (MPV) | WB | ±2 fL or 20% if > 10 fL | 5 RCPA | |
| Metanephrine | Plasma | ±75 pmol/L or 15% if > 500 pmol/L | 5 RCPA | |
| Metanephrine | Urine | ±0,2 μmol/L or 20% if > 1,0 μmol/L | 5 RCPA | |
| Metanephrine, Free | Urine | ±30 nmol/L or 30% if > 100 nmol/L | 5 RCPA | |
| Methemoglobin | WB | ±0,003 | 2 WSLH | |
| Methotrexate | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Methotrexate | Serum | ±0,10 μg/L or 10% if > 1,00 μmol/L | 5 RCPA | |
| Methyoxytyramine | Plasma | ±36 pmol/L or 30% if > 120 pmol/L | 5 RCPA | |
| Mercury | Serum | ±30% or 3 ug/L | 2 WSLH | |
| Mercury | Serum, Urine, WB | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Microalbumin | Urine | ±10% | 2 WSLH | |
| Microalbumin | Urine | ±30% | 4 AAB | |
| Monocytes, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Mycophenolate | Serum | ±0,10 μg/L or 10% if > 1,00 mg/L | 5 RCPA | |
| Myoglobin | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| N-Acetylprocainamide (NAPA) | Serum | ±25% | 3 CAP | |
| Neuron-specific enolase (NSE) | Serum | ±2 μg/L or 10% if > 20 μg/L | 5 RCPA | |
| Neutrophil, count | WB | automated | ±1% or 10% if > 10,0% | 5 RCPA |
| Nickel | Urine | ±40 nmol/L or 10% if > 400 nmol/L | 5 RCPA | |
| Noradrenaline | Urine | ±75 nmol/L or 15% if > 500 nmol/L | 5 RCPA | |
| Normetanephrine | Plasma | ±200 pmol/L or 20% if > 1000 pmol/L | 5 RCPA | |
| Normetanephrine | Urine | ±0,4 μmol/L or 20% if > 2,0 μmol/L | 5 RCPA | |
| Normetanephrine, Free | Urine | ±40 nmol/L or 20% if > 200 nmol/L | 5 RCPA | |
| Nortriptyline | Serum | ±3,0 μg/L or 10% if > 26,0 μg/L | 5 RCPA | |
| N-Telopeptides | Urine | ±80 nmolBCE/L or 10% if > 700 nmolBCE/L | 5 RCPA | |
| Osmolality | Urine | ±10% | 2 WSLH | |
| Osmolality | Serum, Body Fluids | ±8 mmol/kg or 3% if > 266 mmol/kg | 5 RCPA | |
| Osmolality | Urine | ±6 mmol/kg or 2% if > 300 mmol/kg | 5 RCPA | |
| Pancreatic Amylase | Serum | ±30% | 3 CAP | |
| Parathyroid hormone (PTH) | Serum | ±30% | 1 CLIA, 2 WSLH, 4 AAB | |
| Parathyroid Hormone (PTH) | Serum | ±1,0 pmol/L or 12% if > 8,0 pmol/L | 5 RCPA | |
| Partial thromboplastin time (PTT), (aPTT) | Plasma | ±15% | 1 CLIA, 2 WSLH, 4 AAB | |
| Partial thromboplastin time (PTT), (aPTT) | Plasma | ±10 sec or 25% if > 40 sec | 5 RCPA | |
| pCO2 | WB | ±8% or 5 mmHg (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
| pCO2 | WB | ±2 mm Hg or 6% if > 34,0 mm Hg | 5 RCPA | |
| pH | WB | ±0,04 | 1 CLIA, 2 WSLH, 4 AAB, 5 RCPA | |
| pH | Body Fluids | ±0,5 | 2 WSLH | |
| pH | Body Fluids | ±0,02 | 5 RCPA | |
| Phenobarbital | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Phenobarbital | Serum | ±20% | 4 AAB | |
| Phenobarbitone | Serum | ±0,7 mg/L or 10% if > 7,0 mg/L | 5 RCPA | |
| Phenytoin | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Phenytoin | Serum | ±25% | 4 AAB | |
| Phenytoin | Serum | ±0,8 mg/L or 10% if > 7,6 mg/L | 5 RCPA | |
| Phenytoin, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Phosphate | Serum | ±0,06 mmol/L or 8% if > 0,75 mmol/L | 5 RCPA | |
| Phosphate | Urine | ±3 mmol/L or 15% if > 20 mmol/L | 5 RCPA | |
| Phosphorus | Serum | ±10% or 0,3 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Phosphorus | Urine | ±15% or 0,5 mg/dL | 2 WSLH | |
| Platelet count | WB | ±25% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Platelet count | WB | ±25x109/L or 25% If > 100x109/L | 5 RCPA | |
| pO2 | WB | ±15% or 15 mmHg (greater) | 1 CLIA, 2 WSLH | |
| pO2 | WB | ±5 mm Hg or 6% if > 83 mm Hg | 5 RCPA | |
| Porphobilinogen | Urine | ±5 μmol/L or 25% if > 20 μmol/L | 5 RCPA | |
| Porphyrin, Total | Plasma | ±4 nmol/L or 20% if > 20 nmol/L | 5 RCPA | |
| Porphyrin, Total | Urine | ±60 nmol/ or 20% if > 300 nmol/L | 5 RCPA | |
| Porphyrin, Total | Fecal | ±40 μmol/kg or 20% if > 200 μmol/kg | 5 RCPA | |
| Porphyrin, Total RBC | WB | ±0,4 μmol/Lrc or 20% if > 2,0 μmol/Lrc | 5 RCPA | |
| Posaconazole | Serum | ±0,1 mg/L or 10% if > 1,0 mg/L | 5 RCPA | |
| Potassium (K) | Serum | ±0,3 mmol/L | 1 CLIA, 2 WSLH, 3 CAP | |
| Potassium (K) | Urine | ±10% | 2 WSLH | |
| Potassium (K) | Serum | ±0,5 mmol/L | 4 AAB | |
| Potassium (K) | Serum | ±0,2 mmol/L or 5% if > 4,0 mmol/L | 5 RCPA | |
| Potassium (K) | Body Fluids | ±0,4 mmol/L or 10% if > 4 mmol/L | 5 RCPA | |
| Potassium (K) | Urine | ±2 mmol/L or 10% > 20 mmol/L | 5 RCPA | |
| Prealbumin | Serum | ±5,0 mg/dL or 25% (greater) | 3 CAP | |
| Prealbumin | Serum | ±25% | 4 AAB | |
| Prealbumin | Serum | ±0,04 g/L or 20% if > 0,2 g/L | 5 RCPA | |
| Primidone | Serum | ±25% | 3 CAP | |
| Pro B-natriuretic Peptide (proBNP) | Serum | ±30% | 1 CLIA | |
| Procainamide | Serum | ±25% | 3 CAP | |
| Procalcitonin | Serum | ±0,05 ng/mL or 30% if > 0,15 ng/mL | 5 RCPA | |
| Progesterone | Serum | ±25% | 1 CLIA, 2 WSLH, 4 AAB | |
| Progesterone | Serum | ±2 nmol/L or 15% if > 10 nmol/L | 5 RCPA | |
| Prolactin | Serum | ±20% | 1 CLIA, 2 WSLH, 4 AAB | |
| Prolactin | Serum | ±40 mIU/L or 10% if > 400 mIU/L | 5 RCPA | |
| Prostate Specific Antigen (PSA) | Serum | ±20% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH | |
| Prostate Specific Antigen (PSA) | Serum | ±0,9 ng/mL or 30% | 4 AAB | |
| Prostate Specific Antigen (PSA) | Serum, Urine | ±0,4 μg/L or 8% if > 5,0 μg/L | 5 RCPA | |
| Prostate Specific Antigen (PSA), Free | Serum | ±30% or 0,9 ng/mL | 2 WSLH | |
| Prostate Specific Antigen (PSA), Free | Serum | ±0,9 ng/mL or 30% | 4 AAB | |
| Prostate Specific Antigen (PSA), Free | Serum | ±0,2 μg/L or 15% if > 1,4 μg/L | 5 RCPA | |
| Protein, Total | Serum | ±8% | 1 CLIA, 2 WSLH, 3 CAP | |
| Protein, Total | Body Fluids, CSF, Urine | ±10% | 2 WSLH | |
| Protein, Total | Serum | ±10% | 4 AAB | |
| Protein, Total | Urine | ±44% | 4 AAB | |
| Protein, Total | Serum, Body Fluids | ±3,0 g/L or 5% if > 60 g/L | 5 RCPA | |
| Protein, Total | CSF | ±0,05 g/L or 10% if > 0,5 g/L | 5 RCPA | |
| Protein, Total | Urine | ±0,1 g/L or 10% if > 1,00 g/L | 5 RCPA | |
| Protein C, Functional | Plasma | ±12% or 20% if > 60% | 5 RCPA | |
| Protein S, Free Antigen | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Protein S, Free Functional | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Protein S, Total Antigen | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Prothrombin Time (PT) | Serum | ±15% | 1 CLIA, 2 WSLH, 4 AAB | |
| Prothrombin Time (PT) | Plasma | ±2,0 sec or 20% if > 10 sec | 5 RCPA | |
| Quinidine | Serum | ±25% | 3 CAP | |
| RBC, Red Cell count, Erythrocyte Count | WB | automated differential | ±4% | 1 CLIA, 2 WSLH |
| RBC, Red Cell count, Erythrocyte Count | WB | quantitative | ±6% | 4 AAB |
| Red Cell Distribution Width (RDW) | WB | 2% or 20% if > 10% | 5 RCPA | |
| Reticulocyte count | WB | ±30% or 2 SD (greater) | 4 AAB | |
| Reticulocyte count | WB | automated % | ±1,0% or 10% if > 10% | 5 RCPA |
| Reticulocyte count | WB | automated absolute | ±10x109/L or 10% if > 100x109/L | 5 RCPA |
| Reticulocyte count | WB | manual % | ±0,6% or 30% if > 2% | 5 RCPA |
| Reticulocyte count | WB | manual absolute | ±21x109/L or 30% if > 70x109/L | 5 RCPA |
| Rheumatoid Factor (RF) | Serum | ±2 dilutions or positive or negative | 1 CLIA, 2 WSLH | |
| Rheumatoid Factor (RF) | Serum | ±12 IU/mL or 20% if > 60 IU/mL | 5 RCPA | |
| Rubella | Serum | ±2 dilutions or positive or negative or immune or nonimmune | 1 CLIA, 2 WSLH | |
| Salicylates | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Salicylates | Serum | ±25% | 4 AAB | |
| Salicylates | Serum | ±14 mg/L or 10% if > 143,0 mg/L | 5 RCPA | |
| Selenium | Serum | ±0,18 μmol/L or 12% if > 1,50 μmol/L | 5 RCPA | |
| Selenium | Urine | ±0,06 μmol/L or 12% if > 0,50 μmol/L | 5 RCPA | |
| Selenium | WB | ±0,3 μmol/L or 12% if > 2,50 μmol/L | 5 RCPA | |
| Serotonin | Urine | ±0,2 μmol/L or 20% if > 1,0 μmol/L | 5 RCPA | |
| Sex hormone binding globulin (SHBG) | Serum | ±6 nmol/L or 12% if > 50 nmol/L | 5 RCPA | |
| Sirolimus | Serum | ±0,5 μg/L or 10% if > 5,0 μg/L | 5 RCPA | |
| Sodium (Na) | Serum | ±4 mmol/L | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Sodium (Na) | Urine | ±10% or 4 mmol/L | 2 WSLH | |
| Sodium (Na) | Serum | ±3 mmol/L or 2% if > 150 mmol/L | 5 RCPA | |
| Sodium (Na) | Body Fluids | ±6 mmol/L or 4% if > 150 mmol/L | 5 RCPA | |
| Sodium (Na) | Urine | ±4 mmol/L or 10% if > 40 mmol/L | 5 RCPA | |
| Specific Gravity | Urine | ±0,010 | 2 WSLH, 4 AAB | |
| T3 Free, (FT3) Triiodothyronine, Free | Serum | ±0,7 pmol/L or 20% if > 3,5 pmol/L | 5 RCPA | |
| T3, Total Triiodothyronine | Serum | ±30% | 1 CLIA, 2 WSLH, 3 CAP | |
| T3, Total Triiodothyronine | Serum | ±0,2 nmol/L or 15% if > 1,3 nmol/L | 5 RCPA | |
| T3 Uptake | Serum | ±18% | 1 CLIA, 2 WSLH, 3 CAP | |
| T4, Thyroxine | Serum | ±20% or 1,0 µg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| T4, Thyroxine | Serum | ±12 nmol/L or 10% if > 120 nmol/L | 5 RCPA | |
| T4, Free Thyroxine, (FT4) | Serum | ±15% or 0,3 ng/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| T4, Free Thyroxine, (FT4) | Serum | ±1,5 pmol/L or 12% if > 12,0 pmol/L | 5 RCPA | |
| Tacrolimus | Serum | ±0,5 μg/L or 10% if > 5,0 μg/L | 5 RCPA | |
| Testosterone | Serum | ±30% or 20 ng/dL (greater) | 1 CLIA, 2 WSLH, 4 AAB | |
| Testosterone | Serum | ±0,4 nmol/L or 15% if > 2,7 nmol/L | 5 RCPA | |
| Thallium | Serum, Urine | ±1 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Thallium | WB | ±2 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Theophylline | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Theophylline | Serum | ±25% | 4 AAB | |
| Theophylline | Serum | ±0,5 mg/L or 10% if > 5,4 mg/L | 5 RCPA | |
| Thrombin Time (TT) | Plasma | ±3,0 sec or 25% if > 12,0 sec | 5 RCPA | |
| Thyroglobulin | Serum | ±0,2 μg/L or 12% if > 1,7 μg/L | 5 RCPA | |
| Thyroid stimulating Hormone (TSH) | Serum | ±20% or 0,2 mIU/L (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Thyroid Stimulating Hormone (TSH) | Serum | ±0,1 mU/L or 20% if > 0,5 mU/L | 5 RCPA | |
| Tobramycin | Serum | ±20% | 1 CLIA, 3 CAP | |
| Tobramycin | Serum | ±20% | 2 WSLH | |
| Tobramycin | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
| Transferrin | Serum | ±20% | 3 CAP | |
| Transferrin | Serum | ±10% | 4 AAB | |
| Transferrin | Serum | ±0,2 g/L or 8% if > 2,50 g/L | 5 RCPA | |
| Triglycerides | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP | |
| Triglycerides | Body Fluids | ±25% | 2 WSLH | |
| Triglycerides | Serum | ±25% | 4 AAB | |
| Triglycerides | Serum | ±0,2 mmol/L or 12% if > 1,60 mmol/L | 5 RCPA | |
| Triglycerides | Body Fluids | ±0,3 mmol/L or 25% if > 1,2 mmol/L | 5 RCPA | |
| Troponin I | Serum | ±30% or 0,9 ng/mL (greater) | 1 CLIA, 2 WSLH | |
| Troponin I | Serum | ±30% | 4 AAB | |
| Troponin I | Serum | ±0,002 μg/L or 20% if > 0,010 μg/L | 5 RCPA | |
| Troponin I | Serum | ±0,01 μg/L or 20% if > 0,05 μg/L | 5 RCPA | |
| Troponin T | Serum | ±30% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH | |
| Troponin T | Serum | ±30% | 4 AAB | |
| Troponin T | Serum | ±0,001 μg/L or 20% if > 0,050 μg/L | 5 RCPA | |
| Troponin T | Serum | ±10 ng/L or 20% if > 50 ng/L | 5 RCPA | |
| Tryptase | Serum | ±0,6 ug/L or 15% if > 4,0 ug/L | 5 RCPA | |
| Urate | Serum | ±0,030 mmol/L or 8% if > 0,380 mmol/L | 5 RCPA | |
| Urate | Body Fluids | ±0,06 mmol/L or 16% if > 0,38 mmol/L | 5 RCPA | |
| Urate | Urine | ±0,3 mmol/L or 15% if > 2 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Serum | ±9% or 2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB | |
| Urea Nitrogen (BUN) | Urine | ±10% | 2 WSLH | |
| Urea Nitrogen (BUN) | Serum | ±0,5 mmol/L or 12% if > 4,0 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Body Fluids | ±1,0 mmol/L or 24% if > 4,0 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Urine | ±20 mmol/L or 10% if > 200 mmol/L | 5 RCPA | |
| Uric Acid | Serum | ±10% | 1 CLIA, 2 WSLH, 3 CAP | |
| Uric Acid | Serum | ±17% | 4 AAB | |
| Uric Acid | Urine | ±17% or 2 mg/dL | 2 WSLH | |
| Valproate | Serum | ±4,0 mg/L or 10% if > 36,0 mg/L | 5 RCPA | |
| Valproic Acid | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Valproic Acid | Serum | ±25% | 4 AAB | |
| Valproic Acid, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Vanadium | Serum | ±1 nmol/L or 10% if > 10nmol/L | 5 RCPA | |
| Vanadium | Urine | ±2 nmol/L or 10% if > 10nmol/L | 5 RCPA | |
| Vancomycin | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Vancomycin | Serum | ±25% or 1,0 μg/mL (greater) | 4 AAB | |
| Vancomycin | Serum | ±2,0 mg/L or 10% if > 20,3 mg/L | 5 RCPA | |
| Vitamin A | Serum | ±0,2 μmol/L or 12% if > 1,7 μmol/L | 5 RCPA | |
| Vitamin B1 | Serum | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Vitamin B2 | Serum | ±25 nmol/L or 10% if > 250 nmol/L | 5 RCPA | |
| Vitamin B6 | Plasma, WB | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Vitamin B12 | Serum | ±25% or 30 pg/mL (greater) | 1 CLIA, 2 WSLH | |
| Vitamin B12 | Serum | ±25% | 4 AAB | |
| Vitamin B12 | Serum | ±18 pmol/L or 15% if > 120 pmol/L | 5 RCPA | |
| Vitamin C | Serum | ±7 μmol/L or 20% if > 35 μmol/L | 5 RCPA | |
| Vitamin D3 | Serum | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Vitamin E | Serum | ±3 μmol/L or 12% if > 25 μmol/L | 5 RCPA | |
| von Willebrand Activity | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
| von Willebrand factor, Antigen (vWF:Ag) | Plasma | ±3% or 30% if > 10% | 5 RCPA | |
| von Willebrand Collagen binding (vWF:CB) | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
| von Willebrand Ristocetin Cofactor (vWF:rCo) | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
| Voriconazole | Serum | ±0,2 mg/L or 10% if > 2,0 mg/L | 5 RCPA | |
| WBC, White Cell Count, Leukocyte count) | WB | automated differential | ±10% | 1 CLIA, 2 WSLH |
| WBC, White Cell Count, Leukocyte count) | WB | ±15% | 4 AAB | |
| WBC, White Cell Count, Leukocyte count) | WB | ±0.5x109/L or 10% if > 5,0 x109/L | 5 RCPA | |
| WBC Differential | WB | ±3SD based on the percentage of different types of white blood cells in the samples | 1 CLIA, 2 WSLH | |
| WBC Differential | WB | automated differential | ±3% or 30% if > 10% | 5 RCPA |
| Zinc | Serum, Urine | ±2 μmol/L or 10% if > 20,0 μmol/L | 5 RCPA | |
| Zinc | WB | ±6 μmol/L or 10% if > 60 μmol/L | 5 RCPA |
Sources
| Abbreviation | Source |
|---|---|
| 1 CLIA | CLIA – Federal Register |
| 2 WLSH | Wisconsin State Laboratory of Hygiene |
| 3 CAP | College of American Pathologists |
| 4 AAB | American Association of Bioanalysts |
| 5 RCPA | The Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist association Quality Assurance Program |
Total Allowable Error Table (Prior to junio 2024)
| Analyte | Discipline | Fluid | Method | Limit | Source |
|---|---|---|---|---|---|
| 11-Deoxycortisol | Unclassified | 30 nmol/L, 15% | 7 RCPA | ||
| 11-Desoxycortisol | Unclassified | Serum | 27,10% | 5 BV | |
| 17-Hydroxyprogesterone | Unclassified | 3 nmol/L, 20% | 7 RCPA | ||
| 17-Hydroxyprogesterone | Unclassified | Serum | 30,20% | 5 BV | |
| 5HIAA | Unclassified | 20 umol/day, 20% | 7 RCPA | ||
| 5'-Hidroxiindolacetate - Concentration, 2 | Unclassified | Urine | 26,50% | 5 BV | |
| 5'Nucleotidase | Unclassified | Serum | 26,80% | 5 BV | |
| A/C Ratio | Unclassified | 2,5 SD | 2 WSLH | ||
| a1-Acid Glycoprotein | Unclassified | Serum | 16,20% | 5 BV | |
| a1-Antichymotrypsin | Unclassified | Serum | 16,80% | 5 BV | |
| a1-Antitrypsin | Unclassified | Serum | 9,20% | 5 BV | |
| a1-Globulins | Unclassified | Serum | 15,70% | 5 BV | |
| a1-Microglobulin - Concentration, first m | Unclassified | Urine | 43,90% | 5 BV | |
| a2-Globulins | Unclassified | Serum | 12,60% | 5 BV | |
| a2-Macroglobulin | Unclassified | Serum | 7,60% | 5 BV | |
| a2-Microglobulin output, overnight | Unclassified | Urine | 34,70% | 5 BV | |
| a-Amylase | Unclassified | Serum | 15,70% | 5 BV | |
| a-Amylase (pancreatic) | Unclassified | Serum | 17,70% | 5 BV | |
| a-Amylase concentration, random | Unclassified | Urine | 103,70% | 5 BV | |
| Acetaminophen | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
| Acetaminophen | Unclassified | 2,5 mg/mL or 25% | 6 AAB | ||
| Acetaminophen | Unclassified | +/- 15% | 3 NYS | ||
| Acetaminophen | Unclassified | 25% | 2 WSLH | ||
| Acetaminophen | Unclassified | 20% | 8 CFX | ||
| Acetone | Unclassified | 25% | 2 WSLH | ||
| Acid Phosphatase | Unclassified | 1,5 U/L & ug/L, 15% | 7 RCPA | ||
| Acid Phosphatase | Unclassified | Serum | 10,3 | 5 BV | |
| Acid Phosphatase - Total | Unclassified | 1,5 U/L & ug/L, 15% | 7 RCPA | ||
| Acid phosphatase tartrate resistent | Unclassified | Serum | 13,20% | 5 BV | |
| ACTH | Unclassified | 2,0 pmol/L, 10% | 7 RCPA | ||
| Activated Clotting Time | Unclassified | 20% | 6 AAB | ||
| Activated Clotting Time (ACT) | Unclassified | 2 SD | 2 WSLH | ||
| Activated Partial Thrombo Time | Unclassified | 15% | 6 AAB | ||
| Activated Partial Thromboplastine Time | Unclassified | Plasma | 4,50% | 5 BV | |
| Active Renin | Unclassified | 1,0 uU/mL, 25% | 7 RCPA | ||
| Adenosine Deaminase | Unclassified | Serum | 16,70% | 5 BV | |
| Adrenaline | Unclassified | 50 nmol/day, 33% | 7 RCPA | ||
| AFP | Unclassified | 5 kIU/L, 20% | 7 RCPA | ||
| AFP | Unclassified | Centaur | 3 SD | 4 CAP | |
| AFP | Unclassified | Amniotic Fluid | +/- 3 SD | 3 NYS | |
| AFP | Unclassified | Maternal Sera | +/- 3 SD | 3 NYS | |
| AFP | Unclassified | Amniotic Fluid | Centaur | 3 SD | 4 CAP |
| AFPTM | Unclassified | +/- 3 SD | 3 NYS | ||
| AFP-Tumor (Chiron) | Unclassified | Centaur | 3 SD | 4 CAP | |
| Alanine Aminotransferase | Unclassified | 35% | 8 CFX | ||
| Alanine Aminotransferase | Unclassified | 20% | 6 AAB | ||
| Alanine Aminotransferase | Unclassified | Serum | 32,10% | 5 BV | |
| Alanine Aminotransferase | Química | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Alanine Aminotransferase | Unclassified | 8 U/L, 15% | 7 RCPA | ||
| Alanine Aminotransferase | Unclassified | AU640 | 20% | 4 CAP | |
| Alanine Transaminase | Unclassified | 8 U/L, 15% | 7 RCPA | ||
| Alanine Transaminase | Unclassified | AU640 | 20% | 4 CAP | |
| Albumin | Química | +/- 10% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Albumin | Química | AU640 | 10% | 4 CAP | |
| Albumin | Química | 10% | 8 CFX | ||
| Albumin | Química | Serum | 3,90% | 5 BV | |
| Albumin | Química | 2,0 g/L, 10% | 7 RCPA | ||
| Albumin | Unclassified | Cerebrospinal Fluid | BNII | 20% | 4 CAP |
| Albumin | Unclassified | Cerebrospinal Fluid | 0,10 g/L, 10% | 7 RCPA | |
| Albumin | Unclassified | Urine | 0,1 g/L, 10% | 7 RCPA | |
| Albumin | Unclassified | Blood | BNII | 20% | 4 CAP |
| Albumin - Concentration, first morning | Unclassified | Urine | 46,10% | 5 BV | |
| Alcohol | Toxicología | Blood | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | |
| Alcohol | Unclassified | 2,2 mmol/L, 10% | 7 RCPA | ||
| Alcohol | Unclassified | Blood | +/- 10% | 3 NYS | |
| Alcohol (Ethanol) | Unclassified | Urine | Pos/Neg | 2 WSLH | |
| Alcohol | Unclassified | Serum | 25% | 6 AAB | |
| Aldosterone | Unclassified | 75,0 pmol/L, 15% | 7 RCPA | ||
| Aldosterone | Unclassified | Serum | 36,70% | 5 BV | |
| Aldosterone - Concentration | Unclassified | Urine | 39,60% | 5 BV | |
| Alkaline Phosphatase | Unclassified | AU640 | 30% | 4 CAP | |
| Alkaline Phosphatase | Química | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Alkaline Phosphatase | Química | Serum | 11,70% | 5 BV | |
| Alkaline Phosphatase | Unclassified | 15 U/L, 15% | 7 RCPA | ||
| Alkaline Phosphatase | Unclassified | 30% | 6 AAB | ||
| Alkaline Phosphatase | Unclassified | 30% | 8 CFX | ||
| Alkaline phosphatase, bone isoform | Unclassified | Serum | 14,50% | 5 BV | |
| Alpha 1 Antitrypsin | Unclassified | BNII | 3 SD | 4 CAP | |
| Alpha 1 Antitrypsin | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
| Alpha 1 Antitrypsin | Unclassified | 3SD | 6 AAB | ||
| Alpha fetoprotein (Prenatal screen) | Unclassified | 3 SD | 2 WSLH | ||
| Alpha-fetoprotein | Immunology | 5 kIU/L, 20% | 7 RCPA | ||
| Alpha-fetoprotein | Immunology | +/- 3 SD | 1 CLIA, 2 WSLH | ||
| Amikacin | Unclassified | 2,0 mg/L, 10% | 7 RCPA | ||
| Amikacin | Unclassified | 25% | 2 WSLH | ||
| Amikacin | Unclassified | 15% | 8 CFX | ||
| Amiodarone | Unclassified | 0,2 umol/L, 10% | 7 RCPA | ||
| Amitriptyline | Unclassified | 10 umol/L, 10% | 7 RCPA | ||
| Amitriptyline | Unclassified | 15% | 8 CFX | ||
| Ammonia | Unclassified | AU640 | not evaluated | 4 CAP | |
| Ammonia | Unclassified | 3 umol/L, 10% | 7 RCPA | ||
| Ammonia | Unclassified | 2,5 SD | 2 WSLH | ||
| Ammonia | Unclassified | Serum | 10 umol/L or 5% | 6 AAB | |
| Ammonia - Output | Unclassified | Urine | 29,60% | 5 BV | |
| Amphetamines | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Amphetamines | Unclassified | Pos/Neg | 2 WSLH | ||
| Amphetamines | Unclassified | 20% or 2 SD | 3 NYS | ||
| Amphetamines - Qualitative | Unclassified | Presence or Absence | 3 NYS | ||
| Amylase | Química | 15 U/L, 15% | 7 RCPA | ||
| Amylase | Química | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Amylase | Química | AU640 | 30% | 4 CAP | |
| Amylase | Química | 20% | 8 CFX | ||
| Amylase | Unclassified | Urine | 30% | 2 WSLH | |
| Amylase | Unclassified | Urine | AU640 | 3 SD | 4 CAP |
| Androstenedione | Unclassified | Serum | 22,60% | 5 BV | |
| Androstenedione | Unclassified | 2,0 nmol/L | 7 RCPA | ||
| Angiotensin converting enzyme | Unclassified | Plasma | 17,90% | 5 BV | |
| Anti-CMV | Unclassified | Positive or Negative | 3 NYS | ||
| Anti-Human Immunodeficiency virus | Immunology | Reaction or nonreactive | 1 CLIA | ||
| Antinuclear antibody | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA, 3 NYS | ||
| Antistreptolysin O | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA, 3 NYS | ||
| Antithrombin III | Unclassified | Plasma | 8,30% | 5 BV | |
| Apolipoprotein A1 | Unclassified | BNII | 3 SD | 4 CAP | |
| Apolipoprotein A1 | Unclassified | 25 mg/dL or 30% | 6 AAB | ||
| Apolipoprotein A1 | Unclassified | 0,2 g/L, 10% | 7 RCPA | ||
| Apolipoprotein A1 | Unclassified | Serum | 9,10% | 5 BV | |
| Apolipoprotein A1 | Unclassified | 10% | 8 CFX | ||
| Apolipoprotein B | Unclassified | BNII | 3 SD | 4 CAP | |
| Apolipoprotein B | Unclassified | 20 mg/dL or 25% | 6 AAB | ||
| Apolipoprotein B | Unclassified | 0,2 g/L, 10% | 7 RCPA | ||
| Apolipoprotein B | Unclassified | 12% | 8 CFX | ||
| Apolipoprotein B | Unclassified | Serum | 11,60% | 5 BV | |
| Apolipoprotein B100 | Unclassified | BNII | not evaluated | 4 CAP | |
| Ascorbic Acid | Unclassified | Serum | 29,90% | 5 BV | |
| Aso-Antistreptolysin | Unclassified | BNII | 2 SD | 4 CAP | |
| Aspartate Aminotransferase | Unclassified | 20% | 6 AAB | ||
| Aspartate Aminotransferase | Unclassified | 20% | 8 CFX | ||
| Aspartate Aminotransferase | Unclassified | Serum | 15,20% | 5 BV | |
| Aspartate Aminotransferase | Química | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| a-Tocopherol | Unclassified | Serum | 16,20% | 5 BV | |
| Automated Differential | Unclassified | 3SD | 6 AAB | ||
| b2-Microglobulin | Unclassified | Serum | 9% | 5 BV | |
| Barbiturates | Unclassified | 20% or 2 SD | 3 NYS | ||
| Barbiturates | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Barbiturates | Unclassified | Pos/Neg | 2 WSLH | ||
| Basophile, count | Unclassified | Serum | 38,50% | 5 BV | |
| b-Carotene | Unclassified | Serum | 43% | 5 BV | |
| Benzodiazepine | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Benzodiazepine | Unclassified | 20% or 2 SD | 3 NYS | ||
| Benzodiazepine | Unclassified | Pos/Neg | 2 WSLH | ||
| Benzoylecgonine | Unclassified | 20% or 2 SD | 3 NYS | ||
| Beta 2 microglobulin | Unclassified | 0,06 mg/L or 30% | 6 AAB | ||
| Beta Carotene | Unclassified | 0,2 umol/L, 10% | 7 RCPA | ||
| Beta-2 Microglobulin | Unclassified | 0,2 mg/L, 10% | 7 RCPA | ||
| Beta-Hydroxybutyric Acid | Unclassified | 2 SD | 8 CFX | ||
| b-Globulins | Unclassified | Serum | 11,70% | 5 BV | |
| Bicarbonate | Unclassified | 2,0 mmol/L, 10% | 7 RCPA | ||
| Bicarbonate (Total CO2) | Unclassified | 4 mEq/L or 20% | 6 AAB | ||
| Bilirubin - Direct | Unclassified | 50% | 8 CFX | ||
| Bilirubin - Direct | Unclassified | AU640 | 20% or 0,4 mg/dL (greater) | 4 CAP | |
| Bilirubin - Direct | Unclassified | 0,4 mg/dL or 20% | 2 WSLH | ||
| Bilirubin - Neonatal | Unclassified | 31% | 8 CFX | ||
| Bilirubin - Total | Unclassified | 5 umol/L, 10% | 7 RCPA | ||
| Bilirubin - Total | Unclassified | 31% | 8 CFX | ||
| Bilirubin - Total | Unclassified | Serum | 31,10% | 5 BV | |
| Bilirubin - Total | Química | +/- 0,4 mg/dL or +/- 20% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Bilirubin - Total | Unclassified | AU640 | 20% or 0,4 mg/dL (greater) | 4 CAP | |
| Bilirubin - Total | Unclassified | 0,4 mg/dL or 20% | 6 AAB | ||
| Bilirubin - Conjugated | Unclassified | 10 umol/L, 20% | 7 RCPA | ||
| Bilirubin - Conjugated | Unclassified | Serum | 44,50% | 5 BV | |
| Bilirubin - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
| Bilirubin - Neonatal | Unclassified | 0,4 mg/dL or 20% | 2 WSLH | ||
| Blood gas p02 | Química | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Blood gas pCO2 | Química | +/- 5 mm Hg or +/- 8% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Blood gas pH | Química | +/- 0,04 | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| BNP | Unclassified | Centaur | not evaluated | 4 CAP | |
| BNP | Unclassified | 5,0 pg/mL or 20% | 6 AAB | ||
| BNP | Unclassified | 2,0 SD | 2 WSLH | ||
| BPb | Unclassified | +/-4 µg/dL (values <40µg/dL) or +/-10% (values >40µg/dL) | 3 NYS | ||
| Bright CD45-/CD14+ | Unclassified | 3 SD | 2 WSLH | ||
| C Peptide | Unclassified | 1,0 nmol/L, 10% | 7 RCPA | ||
| C Peptide | Unclassified | Serum | 11,70% | 5 BV | |
| C3 Complement | Unclassified | BNII | 3 SD | 4 CAP | |
| C3 Complement | Unclassified | Serum | 8,40% | 5 BV | |
| C4 Complement | Unclassified | BNII | 3 SD | 4 CAP | |
| C4 Complement | Unclassified | Serum | 16% | 5 BV | |
| CA 125 | Unclassified | 2 SD | 2 WSLH | ||
| CA 125 | Unclassified | 20 kU/L, 20% | 7 RCPA | ||
| CA 125 | Unclassified | +/- 3 SD | 3 NYS | ||
| CA 125 | Unclassified | 9 U/mL or 30% | 6 AAB | ||
| CA 125 Antigen | Unclassified | Serum | 38,20% | 5 BV | |
| CA 15-3 | Unclassified | 2 SD | 2 WSLH | ||
| CA 15-3 Antigen | Unclassified | Serum | 15,50% | 5 BV | |
| CA 19-9 | Unclassified | 2 SD | 2 WSLH | ||
| CA 19-9 Antigen | Unclassified | Serum | 44,30% | 5 BV | |
| CA 549 antigen | Unclassified | Serum | 16,20% | 5 BV | |
| CA15-3 | Unclassified | 3 kU/L, 15% | 7 RCPA | ||
| CA15-3 | Unclassified | +/- 3 SD | 3 NYS | ||
| CA19-9 | Unclassified | 3 kU/L, 15% | 7 RCPA | ||
| CA19-9 | Unclassified | +/- 3 SD | 3 NYS | ||
| CA27.29 | Unclassified | +/- 3 SD | 3 NYS | ||
| Caffeine | Unclassified | 15% | 8 CFX | ||
| Calcitonin | Unclassified | 2 ng/L, 10% | 7 RCPA | ||
| Calcium | Unclassified | Urine | 1,0 mg/dL | 6 AAB | |
| Calcium | Unclassified | 1,0 mg/dL | 6 AAB | ||
| Calcium | Unclassified | AU640 | 1 mg/dL | 4 CAP | |
| Calcium | Unclassified | 0,10 mmol/L | 7 RCPA | ||
| Calcium | Unclassified | 8% | 8 CFX | ||
| Calcium | Unclassified | Serum | 2,40% | 5 BV | |
| Calcium | unclassified | Urine | 1 mg/dL | 2 WSLH | |
| Calcium | Unclassified | Urine | AU640 | 31% | 4 CAP |
| Calcium | Unclassified | Urine | 0,20 mmol/L | 7 RCPA | |
| Calcium - Ionized | Unclassified | 10% | 8 CFX | ||
| Calcium - Ionized | Unclassified | Radiometer 725 | 3 SD | 4 CAP | |
| Calcium - Ionized | Unclassified | Urine | 2,10% | 5 BV | |
| Calcium - Concentration, 24h | Unclassified | Urine | 34,10% | 5 BV | |
| Calcium - Output, 24h | Unclassified | Urine | 31% | 5 BV | |
| Calcium - Total | Química | +/- 1,0 mg/dL | 1 CLIA | ||
| Cannabinoid | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Cannabinoid | Unclassified | Pos/Neg | 2 WSLH | ||
| Carbamazepine | Toxicología | 2,0 umol/L, 10% | 7 RCPA | ||
| Carbamazepine | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Carbamazepine | Toxicología | +/- 15% | 3 NYS | ||
| Carbamazepine | Toxicología | Abbott AxSym | 25% | 4 CAP | |
| Carbamazepine | Toxicología | 25% | 8 CFX | ||
| Carbamazepine, free | Unclassified | TDX | 3 SD | 4 CAP | |
| Carbohydrate deficient transferrin | Unclassified | Serum | 15,70% | 5 BV | |
| Carbon Dioxide | Unclassified | 5,0 mmol/L | 2 WSLH | ||
| Carboxyhemoglobin | Unclassified | 3 SD | 2 WSLH | ||
| Carboxyhemoglobin | Unclassified | Radiometer 725 | 3 SD | 4 CAP | |
| Carcinoembryonic Antigen | Unclassified | 1,2 ng/mL or 30% | 6 AAB | ||
| Carcinoembryonic Antigen | Unclassified | Serum | 21,80% | 5 BV | |
| CD19+ | Unclassified | 3 SD | 2 WSLH | ||
| CD2+ | Unclassified | 3 SD | 2 WSLH | ||
| CD20+ | Unclassified | 3 SD | 2 WSLH | ||
| CD3-/CD16+56+ | Unclassified | 3 SD | 2 WSLH | ||
| CD3+ | Unclassified | 3 SD | 2 WSLH | ||
| CD3+/CD4+ | Unclassified | 3 SD | 2 WSLH | ||
| CD3+/CD8+ | Unclassified | 3 SD | 2 WSLH | ||
| CD4+ | Unclassified | 3 SD | 2 WSLH | ||
| CD5+ | Unclassified | 3 SD | 2 WSLH | ||
| CD8+ | Unclassified | 3 SD | 2 WSLH | ||
| CEA | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
| CEA | Unclassified | 2,0 ug/L, 20% | 7 RCPA | ||
| CEA | Unclassified | 1,2 ng/mL or 30% | 2 WSLH | ||
| CEA | Unclassified | +/- 3 SD | 3 NYS | ||
| Cell Identification | Hematología | 90% or greater consensus on identification | 1 CLIA, 3 NYS | ||
| Ceruloplasmin | Unclassified | BNII | 3 SD | 4 CAP | |
| Ceruloplasmin | Unclassified | Serum | 7,80% | 5 BV | |
| Chloride | Química | 3,0 mmol/L | 7 RCPA | ||
| Chloride | Química | +/- 5% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Chloride | Química | Radiometer 725 | 5% | 4 CAP | |
| Chloride | Química | AU640 | 5% | 4 CAP | |
| Chloride | Química | 5% | 8 CFX | ||
| Chloride | Química | Serum | 1,50% | 5 BV | |
| Chloride | Unclassified | Urine | 5% | 2 WSLH | |
| Chloride | Unclassified | Urine | AU640 | 3 SD | 4 CAP |
| Chloride | Unclassified | Sweat | 2 mmol/L, 10% | 7 RCPA | |
| Chloride | Unclassified | Urine | 2,0 mmol/L, 10% | 7 RCPA | |
| Cholesterol | Unclassified | 0,50 mmol/L, 5% | 7 RCPA | ||
| Cholesterol | Unclassified | AU640 | 10% | 4 CAP | |
| Cholesterol | Unclassified | Serum | 9% | 5 BV | |
| Cholesterol - HDL | Unclassified | 11% | 8 CFX | ||
| Cholesterol - HDL | Química | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Cholesterol - HDL | Unclassified | ||||
| Cholesterol - HDL | Unclassified | 0,20 mmol/L, 10% | 7 RCPA | ||
| Cholesterol - HDL | Unclassified | 30% | 6 AAB | ||
| Cholesterol - HDL | Unclassified | Serum | 11,10% | 5 BV | |
| Cholesterol - HDL | Unclassified | AU640 | 30% | 4 CAP | |
| Cholesterol - LDL | Unclassified | 15% | 8 CFX | ||
| Cholesterol - LDL | Unclassified | Non-graded analyte | 3 NYS | ||
| Cholesterol - LDL | Unclassified | 30% | 2 WSLH | ||
| Cholesterol - Total | Unclassified | 9% | 8 CFX | ||
| Cholesterol - Total | Unclassified | 10% | 6 AAB | ||
| Cholesterol - Total | Química | +/- 10% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Cholinesterase | Unclassified | Serum | 8,90% | 5 BV | |
| Cholinesterase, catalitic activity | Unclassified | Serum | 7,40% | 5 BV | |
| CK2 Isoenzyme (CKMB) | Unclassified | 3SD | 6 AAB | ||
| CO2 | Unclassified | AU640 | 3 SD | 4 CAP | |
| CO2 - Total | Unclassified | 20% | 8 CFX | ||
| Cocaine-Metabolite | Unclassified | Pos/Neg | 2 WSLH | ||
| Cocaine-Metabolite | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Complement C3 | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
| Complement C4 | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
| Conjugated Bilirubin, Neonatal | Unclassified | 10 umol/L, 20% | 7 RCPA | ||
| Copper | Unclassified | Plasma | 11,80% | 5 BV | |
| Copper | Unclassified | Serum | 7,70% | 5 BV | |
| Cortisol | Endocrinology | 30 nmol/L, 15% | 7 RCPA | ||
| Cortisol | Endocrinology | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Cortisol | Endocrinology | 30% | 8 CFX | ||
| Cortisol | Endocrinology | Serum | 29,80% | 5 BV | |
| Cortisol | Endocrinology | Centaur | 25% | 4 CAP | |
| C-Propeptide type I procollagen | Unclassified | Serum | 11,60% | 5 BV | |
| cPSA | Unclassified | +/- 3 SD | 3 NYS | ||
| C-Reactive protein | Unclassified | Serum | 68,30% | 5 BV | |
| Creatine Kinase | Química | +/- 30% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Creatine Kinase | Química | Serum | 30,30% | 5 BV | |
| Creatine Kinase | Unclassified | 15 U/L, 15% | 7 RCPA | ||
| Creatine Kinase | Unclassified | 30% | 6 AAB | ||
| Creatine Kinase | Unclassified | 30% | 8 CFX | ||
| Creatine Kinase isoenzymes | Química | MB elevated (present or absent) or Target value +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Creatine Kinase MB | Unclassified | 6 U/L & ug/L, 15% | 7 RCPA | ||
| Creatine Kinase MB | Unclassified | Centaur | 3 SD | 4 CAP | |
| Creatine Kinase MB, % | Unclassified | Serum | 16,50% | 5 BV | |
| Creatine Kinase MB, activity | Unclassified | 40% | 8 CFX | ||
| Creatine Kinase MB, activity | Unclassified | Serum | 24,10% | 5 BV | |
| Creatine Kinase MB, mass | Unclassified | 2 SD | 8 CFX | ||
| Creatine Kinase MB, mass | Unclassified | Serum | 31,20% | 5 BV | |
| Creatine Kinase MB, qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
| Creatine Kinase, Total | Unclassified | AU640 | 30% | 4 CAP | |
| Creatinine | Química | AU640 | 15% or 0,3 mg/dL (greater) | 4 CAP | |
| Creatinine | Química | 0,01 mmol/L, 10% | 7 RCPA | ||
| Creatinine | Química | +/- 0,3 mg/dL or +/- 15% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Creatinine | Química | 25% | 8 CFX | ||
| Creatinine | Química | Serum | 6,90% | 5 BV | |
| Creatinine | Unclassified | Urine | AU640 | 17% | 4 CAP |
| Creatinine | Unclassified | Urine | 0,5 mmol/L, 10% | 7 RCPA | |
| Creatinine | Unclassified | Urine | 3 mg/dL or 15% | 6 AAB | |
| Creatinine - Quantitative | Unclassified | Urine | 0,3 mg/dL or 17% | 2 WSLH | |
| Creatinine - Semi Quantitative | Unclassified | Urine | 2 WSLH | ||
| Creatinine Clearence | Unclassified | Patient- | 16% | 5 BV | |
| Creatinine - Concentration | Unclassified | Urine | 28,40% | 5 BV | |
| Creatinine - Output | Unclassified | Urine | 15,40% | 5 BV | |
| CRP | Unclassified | BNII | 2 SD | 4 CAP | |
| CRP | Unclassified | 0,4 mg/dL or 3 SD% | 6 AAB | ||
| Cryptococcus neoformans Antigen | Unclassified | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
| CSF Protein | Unclassified | AU640 | 2 SD | 4 CAP | |
| C-Telopeptide type I procollagen | Unclassified | Serum | 14,10% | 5 BV | |
| Cyclosporine | Unclassified | TDX | 3 SD | 4 CAP | |
| Cystein | unclassified | Plasma | 8,30% | 5 BV | |
| d-Dimer | Unclassified | 30% | 6 AAB | ||
| d-Dimer - Interpretation | Unclassified | Pos/Neg | 2 WSLH | ||
| d-Dimer - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
| d-Dimer - Semi Quantitative | unclassified | Pos/Neg | 2 WSLH | ||
| Dehydroepiandrosterone sulfate | Unclassified | Serum | 22,20% | 5 BV | |
| Deoxipyridinoline/creatinine, 24h | Unclassified | Urine | 21,20% | 5 BV | |
| Deoxipyridinoline/creatinine, morning sp | Unclassified | Urine | 33% | 5 BV | |
| Desipramine | Unclassified | 15% | 8 CFX | ||
| DHEA Sulfate | Unclassified | 2,5 SD | 2 WSLH | ||
| DHEA Sulphate | Unclassified | 2 SD | 8 CFX | ||
| DHEA Sulphate | Unclassified | 1,0 umol/L, 10% | 7 RCPA | ||
| Digoxin | Toxicología | Centaur | 20% or 0,2 ng/mL (greater) | 4 CAP | |
| Digoxin | Toxicología | 15% or 0,2 ng/mL | 3 NYS | ||
| Digoxin | Toxicología | 0,2 nmol/L, 10% | 7 RCPA | ||
| Digoxin | Toxicología | +/- 20% or 0,2 ng/mL (greater) | 1 CLIA, 2 WSLH, 6 AAB | ||
| Digoxin | Toxicología | 25% | 8 CFX | ||
| Dipeptidyl-peptidase IV | Unclassified | Plasma | 10,90% | 5 BV | |
| Direct Bilirubin | Unclassified | 0,4 mg/dL or 20% | 6 AAB | ||
| Disopyramide | Unclassified | 2,0 umol/L, 10% | 7 RCPA | ||
| Disopyramide | Unclassified | 15% | 8 CFX | ||
| DMF | Unclassified | 0,45 mmol/L or 30% | 6 AAB | ||
| Dopamine | Unclassified | 0,25 umol/day, 25% | 7 RCPA | ||
| DPD - Free | Unclassified | Urine | 15 nmol/L, 15% | 7 RCPA | |
| DPD - Total | Unclassified | Urine | 15 nmol/L, 15% | 7 RCPA | |
| Elastase-Pl | Unclassified | Plasma | 16,50% | 5 BV | |
| Eosinophils, count | Unclassified | Blood | 37,10% | 5 BV | |
| EP | Unclassified | +/-6 µg/dL (values <40µg/dL) or +/-15% (values >40µg/dL) | 3 NYS | ||
| Erythrocites, count | Unclassified | Blood | 4,40% | 5 BV | |
| Erythrocites, count | Hematología | +/- 6% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Erythrocyte Sedimentation Rate (ESR) | Unclassified | 3SD | 6 AAB | ||
| Erythrocyte Sedimentation Rate (ESR) - Rapid | Unclassified | 3SD | 6 AAB | ||
| Erythrocytes | Unclassified | 6% | 6 AAB | ||
| Estradiol | Unclassified | 3 pg/mL or 30% | 6 AAB | ||
| Estradiol | Unclassified | 3 ng/mL or 30% | 2 WSLH | ||
| Estradiol | Unclassified | 2 SD | 8 CFX | ||
| Estradiol | Unclassified | +/-25% or 30 pg/mL | 3 NYS | ||
| Estradiol | Unclassified | Urine | 27% | 5 BV | |
| Estriol | Unclassified | 2,5 SD | 2 WSLH | ||
| Estriol - Total | Unclassified | 2 SD | 8 CFX | ||
| Estriol - Unconjugated | Unclassified | 2 SD | 8 CFX | ||
| Estrogen | Unclassified | 2,5 SD | 2 WSLH | ||
| Ethanol | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Ethanol | Unclassified | Urine | HP GLC | 25% or 9 mg/dL (greater) | 4 CAP |
| Ethanol | unclassified | 20% or 2 SD | 3 NYS | ||
| Ethanol | Unclassified | Blood | HP GLC | 25% | 4 CAP |
| Ethanol | Unclassified | 15% | 8 CFX | ||
| Ethosuximide | Toxicología | 3 umol/L, 10% | 7 RCPA | ||
| Ethosuximide | Toxicología | +/- 20% | 1 CLIA, 2 WSLH | ||
| Ethosuximide | Toxicología | +/- 15% | 3 NYS | ||
| Ethosuximide | Toxicología | 15% | 8 CFX | ||
| Factor VII coagulation | Unclassified | Plasma | 0,107 | 5 BV | |
| Factor VIII coagulation | Unclassified | Plasma | 0,089 | 5 BV | |
| Faecal Percent Dry Weight | Unclassified | 1, 10% | 7 RCPA | ||
| Faecal Total Porphyrin | Unclassified | 15 umol/kg, 15% | 7 RCPA | ||
| Fentanyl | Unclassified | 20% or 2 SD | 3 NYS | ||
| Ferritin | Unclassified | 6,0 ug/L, 15% | 7 RCPA | ||
| Ferritin | unclassified | 4,5 ng/mL or 30% | 2 WSLH | ||
| Ferritin | Unclassified | 4,5 ng/mL or 30% | 6 AAB | ||
| Ferritin | Unclassified | Centaur | 3 SD | 4 CAP | |
| Ferritin | Unclassified | 19,30% | 8 CFX | ||
| Ferritine | unclassified | Serum | 17,30% | 5 BV | |
| Fibrinogen | Hematología | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Fibrinogen | Hematología | Plasma | 13,60% | 5 BV | |
| Folate | Unclassified | Serum | Centaur | 3 SD | 4 CAP |
| Folate | Unclassified | 2 SD | 8 CFX | ||
| Folate | Unclassified | 1,0 umol/day, 30% | 7 RCPA | ||
| Folate | Unclassified | 0,9 ng/mL or 30% | 2 WSLH | ||
| Folate | Unclassified | 0,9 ng/mL or 30% | 6 AAB | ||
| Folate | Unclassified | Serum | 39% | 5 BV | |
| Folate | Unclassified | Blood-Erythrocytes | 26,70% | 5 BV | |
| Folic Acid | Unclassified | +/- 30% or 2,0 ng/mL | 3 NYS | ||
| Follicle Stimulating Hormone (FSH) | Unclassified | 2 SD | 8 CFX | ||
| Follicle Stimulating Hormone (FSH) | Unclassified | Serum | 16,70% | 5 BV | |
| Follicle Stimulating Hormone (FSH) | Unclassified | 2 mIU/mL or 25% | 6 AAB | ||
| fPSA | Unclassified | +/- 3 SD | 3 NYS | ||
| Fractional Carboxyhemoglobin | Unclassified | 0,02 | 7 RCPA | ||
| Fractional Methemoglobin | Unclassified | 1,0, 10% | 7 RCPA | ||
| Fractional Oxyhemoglobin | Unclassified | 3, 4% | 7 RCPA | ||
| Free Estriol | Unclassified | +/-25% or 3,0 ng/mL | 3 NYS | ||
| Free phenytoin | Unclassified | +/- 20% | 3 NYS | ||
| Free PSA | Unclassified | 1,5 ug/L, 15% | 7 RCPA | ||
| Free T3 | Unclassified | 3,0 pmol/L | 7 RCPA | ||
| Free T3 | Unclassified | 3 SD | 2 WSLH | ||
| Free T4 (Endocrinology) | Endocrinology | 1,5 pmol/L, 15% | 7 RCPA | ||
| Free T4 (General Chemistry) | Química | 3 pmol/L, 15% | 7 RCPA | ||
| Free thyroxine | Endocrinology | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS | ||
| Free thyroxine (FT4) | Unclassified | Serum | 9,90% | 5 BV | |
| Fructosamine | Unclassified | 30 umol/L, 10% | 7 RCPA | ||
| Fructosamine | Unclassified | Serum | 4,50% | 5 BV | |
| Follicle Stimulating Hormone (FSH) | Unclassified | 4,0 IU/L, 20% | 7 RCPA | ||
| Follicle Stimulating Hormone (FSH) | Unclassified | Centaur | 3 SD | 4 CAP | |
| Follicle Stimulating Hormone (FSH) | Unclassified | 2 mIU/mL or 25% | 2 WSLH | ||
| Follicle Stimulating Hormone (FSH) | Unclassified | +/-25% | 3 NYS | ||
| Galactosy hydroxylisine | Unclassified | Serum | 16,80% | 5 BV | |
| Gamma-Glutamyl Transferase | Unclassified | +/- 30% | 3 NYS | ||
| Gamma-Glutamyl Transferase | Unclassified | 20% | 2 WSLH | ||
| Gamma-Glutamyl Transferase | Unclassified | 30% | 8 CFX | ||
| Gamma-Glutamyl Transferase | unclassified | 10 IU/L or 20% | 6 AAB | ||
| Gamma-Glutamyl Transferase | Unclassified | Serum | 22,20% | 5 BV | |
| Gamma-Glutamyl Transferase | Unclassified | 8 U/L, 15% | 7 RCPA | ||
| Gamma-Glutamyl Transferase | Unclassified | AU640 | 3 SD | 4 CAP | |
| Gastrin | Unclassified | 25 pmol/L, 10% | 7 RCPA | ||
| Gentamicin | Toxicología | 0,5 mg/L, 10% | 7 RCPA | ||
| Gentamicin | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Gentamicin | Toxicología | +/- 15% | 3 NYS | ||
| Gentamicin | Toxicología | Abbott AxSym | 25% | 4 CAP | |
| Gentamicin | Toxicología | 20% | 8 CFX | ||
| g-Globulins | Unclassified | Serum | 16,80% | 5 BV | |
| Globulins, total | Unclassified | Serum | 8% | 5 BV | |
| Glucose | Química | Radiometer 725 | 10% or 6 mg/dL (greater) | 4 CAP | |
| Glucose | Química | AU640 | 10% or 6 mg/dL (greater) | 4 CAP | |
| Glucose | Química | 0,5 mmol/L, 10% | 7 RCPA | ||
| Glucose | Química | +/- 6 mg/dL or +/- 10% (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Glucose | Química | Serum | 6,30% | 5 BV | |
| Glucose | Unclassified | Urine | 10% | 2 WSLH | |
| Glucose | Unclassified | Cerebrospinal Fluid | 10% | 2 WSLH | |
| Glucose | Unclassified | Whole Blood | 20 mg/dL or 20% | 2 WSLH | |
| Glucose | Unclassified | Gases en sangre | 1,0 mmol/day, 10% | 7 RCPA | |
| Glucose | Unclassified | Cerebrospinal Fluid | 1,0 mmol/L, 10% | 7 RCPA | |
| Glucose | Unclassified | Urine | 1,0 mmol/L, 10% | 7 RCPA | |
| Glucose | Unclassified | Urine | AU640 | 10% or 6 g/24 hs (greater) | 4 CAP |
| Glucose | Unclassified | 0,3 mmol/L, 8,0% | 8 CFX | ||
| Glucose | Unclassified | Whole Blood | 6 mg/dL or 10% | 6 AAB | |
| Glucose - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
| Glucose-6-phosphate-1-dehydrogenase | Unclassified | Blood-Erythrocytes | 38,50% | 5 BV | |
| Glutathione Peroxidase | Unclassified | Serum | 11,70% | 5 BV | |
| Glycated Albumin | Unclassified | Serum | 7,20% | 5 BV | |
| Glycated Hemoglobin A1c | Unclassified | 9% | 8 CFX | ||
| Glycated total protein | Unclassified | Serum | 3,70% | 5 BV | |
| Glycohemoglobin | Unclassified | 1,00% or 25% | 6 AAB | ||
| Growth Hormone | Unclassified | 2 mU/L, 20% | 7 RCPA | ||
| Haptoglobin | Unclassified | BNII | not evaluated | 4 CAP | |
| Haptoglobin | Unclassified | Plasma or Serum | 27,30% | 5 BV | |
| hCG | Unclassified | 32% | 8 CFX | ||
| hCG | Unclassified | Maternal Sera | +/- 3 SD | 3 NYS | |
| hCG - Quantitative | Unclassified | Centaur | 3 SD | 4 CAP | |
| hCG - Qualitative | Unclassified | Serum | Pos/Neg | 2 WSLH | |
| hCG - Quantitative | Unclassified | 3,0 IU/L, 15% | 7 RCPA | ||
| hCG - Quantitative | Unclassified | Urine | 5 IU/L, 10% | 7 RCPA | |
| HDL 1 cholesterol | Unclassified | Serum | 11,50% | 5 BV | |
| HDL 2 cholesterol | Unclassified | Serum | 23,90% | 5 BV | |
| HDL 3 cholesterol | Unclassified | Serum | 9,80% | 5 BV | |
| Hematocrit | Hematología | +/- 6% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Hematocrit | Hematología | Blood | 4,10% | 5 BV | |
| Hemoglobin | Hematología | +/- 7% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Hemoglobin | Hematología | Blood | 4,10% | 5 BV | |
| Hemoglobin A1c | Unclassified | Serum | 4,40% | 5 BV | |
| Hemoglobin A1c | Unclassified | 1,0 or 25% | 2 WSLH | ||
| Hemoglobin A1c | Unclassified | 0,5, 5% | 7 RCPA | ||
| Hemoglobin concentration | Unclassified | 3 g/L, 3% | 7 RCPA | ||
| Hemoglobin - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
| Hemoglobin - Total | Unclassified | 7% | 2 WSLH | ||
| Hemoglobin,Total A1 | Unclassified | 1,0 or 25% | 2 WSLH | ||
| Hepatitis (Anti-HBc HBsAg HBeAg Anti-HCV ) | Unclassified | Reactive (Positive) or Nonreactive (Negative) | 3 NYS | ||
| Hepatitis (HBsAg, anti-HBc, HBeAg) | Immunology | Reactive (positive) or nonreactive (negative) | 1 CLIA | ||
| Heterophile | unclassified | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
| high sensitivity CRP | Unclassified | 0,4 mg/L or 3 SD% | 6 AAB | ||
| high sensitivity CRP | Unclassified | BNII | not evaluated | 4 CAP | |
| high sensitivity CRP | Unclassified | 2,0 SD | 2 WSLH | ||
| HMMA | Unclassified | 20 umol/day, 20% | 7 RCPA | ||
| Homocysteine | Unclassified | Non-graded analyte | 3 NYS | ||
| Homocysteine | Unclassified | IMX | 3 SD | 4 CAP | |
| Homocysteine | Unclassified | 2,5 umol/L or 20% | 6 AAB | ||
| Homocysteine | Unclassified | Plasma | 17,70% | 5 BV | |
| Homocysteine | Unclassified | 15% | 8 CFX | ||
| Human Chorionic Gonadotropin | Endocrinology | +/- 3 SD or (positive or negative) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Human Chorionic Gonadotropin | Unclassified | 3SD | 6 AAB | ||
| HVA | Unclassified | 8 umol/day, 25% | 7 RCPA | ||
| Hydroxiproline/creatinine | Unclassified | Serum | 32,90% | 5 BV | |
| Hydroxiproline/minute, night | Unclassified | Urine | 0,43% | 5 BV | |
| Hydroxyproline | Unclassified | Urine | 10 umol/L, 10% | 7 RCPA | |
| IBC - Total | Unclassified | 25% | 8 CFX | ||
| IBC - Unsaturated | Unclassified | 2 SD | 8 CFX | ||
| IgA | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
| IgA | Unclassified | Blood | BNII | 3 SD | 4 CAP |
| IgB | Immunology | +/- 3 SD | 1 CLIA | ||
| IgE | Unclassified | 4,0 IU/L, 20% | 7 RCPA | ||
| IgE | Unclassified | Opt | 3SD | 6 AAB | |
| IgE | Unclassified | 3SD | 6 AAB | ||
| IgE | Unclassified | +/- 3 SD | 3 NYS | ||
| IGF-1 | Unclassified | 3 nmol/L, 15% | 7 RCPA | ||
| IgG | Immunology | +/- 25% | 1 CLIA, 3 NYS, 6 AAB | ||
| IgG | Unclassified | Blood | BNII | 3 SD | 4 CAP |
| IgG | Unclassified | Cerebrospinal Fluid | BNII | 3 SD | 4 CAP |
| IgG | Unclassified | Blood | BNII | 25% | 4 CAP |
| IgM | Immunology | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB | ||
| IgM | Unclassified | Blood | BNII | 3 SD | 4 CAP |
| Imipramine | Unclassified | 15% | 8 CFX | ||
| Immunofix | Unclassified | Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
| Immunofixation | Unclassified | Serum | Sebia Hydrasis LS | 90% consensus | 4 CAP |
| Immunoglobin G | Unclassified | Cerebrospinal Fluid | 0,1 g/L, 10% | 7 RCPA | |
| Immunoglobulin A | Unclassified | Serum | 13,50% | 5 BV | |
| Immunoglobulin G | Unclassified | Serum | 8% | 5 BV | |
| Immunoglobulin M | Unclassified | Serum | 16,80% | 5 BV | |
| Immunoglobulins K chain | Unclassified | Serum | 8% | 5 BV | |
| Immunoglobulins l chain | Unclassified | Serum | 8,60% | 5 BV | |
| Infectious mononucleosis | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
| INR | Unclassified | 2 SD | 2 WSLH | ||
| Insulin | Unclassified | 5 mU/L, 25% | 7 RCPA | ||
| Insulin | Unclassified | +/-25% or 3,0 uU/mL | 3 NYS | ||
| Insulin | Unclassified | Serum | 32,90% | 5 BV | |
| Interferon receptor | Unclassified | Blood-Leukocyte | 17,70% | 5 BV | |
| Interleukin-1B | Unclassified | Serum | 36,50% | 5 BV | |
| Interleukin-8 | Unclassified | Serum | 29,60% | 5 BV | |
| Ionised Calcium | Unclassified | 0,05 mmol/L | 7 RCPA | ||
| Ionized Calcium | Unclassified | 0,25 mmol/L | 6 AAB | ||
| Ionized Calcium | Unclassified | 0,13 mmol/L | 2 WSLH | ||
| Iron | Unclassified | 5 umol/L | 7 RCPA | ||
| Iron | Unclassified | 31% | 8 CFX | ||
| Iron | Unclassified | Blood-Leukocyte | 30,70% | 5 BV | |
| Iron | Unclassified | AU640 | 20% | 4 CAP | |
| Iron | Unclassified | 20% | 6 AAB | ||
| Iron Binding Capacity | Unclassified | 20% | 2 WSLH | ||
| Iron Binding Capacity | Unclassified | AU640 | 20% | 4 CAP | |
| Iron Saturation | Unclassified | Calculated | 3 SD | 4 CAP | |
| Iron, total | Química | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Isopropanol | Unclassified | HP GLC | not evaluated | 4 CAP | |
| Ketones - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
| Lactate | Unclassified | AU640 | 2 SD | 4 CAP | |
| Lactate | Unclassified | 1,0 mmol/L, 10% | 7 RCPA | ||
| Lactate | Unclassified | 1,0 mmol/day, 10% | 7 RCPA | ||
| Lactate | Unclassified | 0,2 mmol/L or 2SD | 2 WSLH | ||
| Lactate | Unclassified | Blood | 30,40% | 5 BV | |
| Lactate | Unclassified | 3% | 8 CFX | ||
| Lactate | Unclassified | Radiometer 725 | 4 CAP | ||
| Lactate | Unclassified | Cerebrospinal Fluid | 0,1 mmol/L, 10% | 7 RCPA | |
| Lactate Dehydrogenase (LDH) | Unclassified | 30 U/L, 15% | 7 RCPA | ||
| Lactate Dehydrogenase (LDH) | Unclassified | AU640 | 20% | 4 CAP | |
| Lactate Dehydrogenase (LDH) | Unclassified | 20% | 6 AAB | ||
| Lactate Dehydrogenase (LDH) | Unclassified | 20% | 8 CFX | ||
| Lactate Dehydrogenase (LDH) | Química | +/- 20% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Lactate Dehydrogenase (LDH) | Química | Serum | 0,114 | 5 BV | |
| Lactate dehydrogenase 1 isoform (LDH1) | Unclassified | Serum | 8,20% | 5 BV | |
| Lactate dehydrogenase 2 isoform (LDH2) | Unclassified | Serum | 5,70% | 5 BV | |
| Lactate dehydrogenase 3 isoform (LDH3) | Unclassified | Serum | 5,80% | 5 BV | |
| Lactate dehydrogenase 4 isoform (LDH4) | Unclassified | Serum | 11% | 5 BV | |
| Lactate dehydrogenase 5 isoform (LDH5) | Unclassified | Serum | 14,80% | 5 BV | |
| Lactoferrin | Unclassified | Opt | 0,5 mg/mL or 20% | 6 AAB | |
| Lactoferrin | Unclassified | Plasma | 16,40% | 5 BV | |
| LD Isoenzymes 3-5 | Unclassified | 3,00% or 30% | 6 AAB | ||
| LDH isoenzymes | Química | LDH1/LDH2 (+ or -) or Target value +/- 30% | 1 CLIA, 3 NYS | ||
| LDL Cholesterol | Unclassified | Serum | 13,60% | 5 BV | |
| LDL- Cholesterol | Unclassified | AU640 | 20% | 4 CAP | |
| LDL Cholesterol - Direct | Unclassified | 15 mg/dL or 20% | 6 AAB | ||
| LDL receptor mRNA | Unclassified | Serum | 24,10% | 5 BV | |
| Lead | Toxicología | Blood | +/- 10% or +/- 4 mcg/dL (greater) | 1 CLIA, 2 WSLH | |
| Lead | Unclassified | Blood | Spectra AA | 10% or 4 ug/dL (greater) | 4 CAP |
| Leukocytes | Unclassified | 15% | 6 AAB | ||
| Leukocytes, count | Hematología | +/- 15% | 1 CLIA | ||
| Leukocytes, count | Unclassified | Plasma | 14,60% | 5 BV | |
| Luteinizing Hormone (LH) | Unclassified | Centaur | 3 SD | 4 CAP | |
| Luteinizing Hormone (LH) | Unclassified | 2,5 SD | 2 WSLH | ||
| Luteinizing Hormone (LH) | Unclassified | 2,0 IU/L, 20% | 7 RCPA | ||
| Luteinizing Hormone (LH) | Unclassified | +/-25% or 1,5 IU/L | 3 NYS | ||
| Lignocaine | Unclassified | 2,0 umol/L, 10% | 7 RCPA | ||
| Lipase | Unclassified | 40 U/L, 20% | 7 RCPA | ||
| Lipase | Unclassified | 37% | 8 CFX | ||
| Lipase | Unclassified | 30% | 2 WSLH | ||
| Lipase | Unclassified | AU640 | 30% | 4 CAP | |
| Lipase | Unclassified | 30% | 6 AAB | ||
| Lipase | Unclassified | Serum | 29,10% | 5 BV | |
| Lipoprotein (a) | Unclassified | 2 SD | 8 CFX | ||
| Lipoprotein (a) | Unclassified | 10 mg/dL or 30% | 6 AAB | ||
| Lipoprotein (a) | Unclassified | Serum | 28,80% | 5 BV | |
| Lithium | Toxicología | AVL 9180 | 20% or 0,3 mEq/L (greater) | 4 CAP | |
| Lithium | Toxicología | 0,2 mmol/L | 7 RCPA | ||
| Lithium | Toxicología | +/- 20% or 0,3 mmol/L | 1 CLIA, 2 WSLH, 6 AAB | ||
| Lithium | Toxicología | +/- 15% or 0,3 mmol/L | 3 NYS | ||
| Lithium | Toxicología | 10% | 8 CFX | ||
| Luteinizing Hormone (LH) | Unclassified | 2 SD | 8 CFX | ||
| Luteinizing Hormone (LH) | Unclassified | 2 mIU/mL or 25% | 6 AAB | ||
| Luteinizing Hormone (LH) | Unclassified | Serum | 19,80% | 5 BV | |
| Lymphocytes, count | Unclassified | Blood | 16% | 5 BV | |
| Magnesium | Química | 3 mmol/L | 7 RCPA | ||
| Magnesium | Química | 0,1 mmol/L, 12% | 8 CFX | ||
| Magnesium | Química | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Magnesium | Química | Blood-Leukocyte | 21,20% | 5 BV | |
| Magnesium | Química | Blood-Erythrocytes | 7,80% | 5 BV | |
| Magnesium | Química | Serum | 4,80% | 5 BV | |
| Magnesium | Unclassified | AU640 | 25% | 4 CAP | |
| Magnesium | Unclassified | Urine | 25% | 2 WSLH | |
| Magnesium | Unclassified | Urine | AU640 | 25% | 4 CAP |
| Magnesium - Ionized | Unclassified | 10% | 8 CFX | ||
| Magnesium (serum) | Unclassified | Urine | 0,12 mmol/L | 7 RCPA | |
| Magnesium - Concentration, 24h | Unclassified | Urine | 52,20% | 5 BV | |
| Magnesium, ionized | Unclassified | Urine | 2,90% | 5 BV | |
| Magnesium - Output, 24h | Unclassified | Urine | 45% | 5 BV | |
| Mean corpuscular hemoglobin (HCM) | Unclassified | Blood-Erythrocytes | 2,70% | 5 BV | |
| Mean corpuscular hemoglobin concentration | Unclassified | Blood-Erythrocytes | 2,20% | 5 BV | |
| Mean corpuscular volume (MCV) | Unclassified | 3 SD | 2 WSLH | ||
| Mean corpuscular volume (MCV) | Unclassified | Blood-Erythrocytes | 2,30% | 5 BV | |
| Mean platelet volume (MPV) | Unclassified | Blood-Platelets | 5,80% | 5 BV | |
| Metanephrine | Unclassified | 0,5 umol/day, 33% | 7 RCPA | ||
| Methadone | Unclassified | Pos/Neg | 2 WSLH | ||
| Methadone | Unclassified | 20% or 2 SD | 3 NYS | ||
| Methanol | Unclassified | HP GLC | not evaluated | 4 CAP | |
| Methemoglobin | Unclassified | 3 SD | 2 WSLH | ||
| Methemoglobin | Unclassified | Radiometer 725 | 2% | 4 CAP | |
| Methotrexate | Unclassified | 0,1 umol/L, 10% | 7 RCPA | ||
| Methotrexate | Unclassified | 25% | 8 CFX | ||
| Methqualone | Unclassified | Pos/Neg | 2 WSLH | ||
| Microalbumin | Unclassified | Urine | AU640 | 3 SD | 4 CAP |
| Microalbumin | Unclassified | Urine | 10 mg/L or 25% | 6 AAB | |
| Microalbumin - Quantitative | Unclassified | 2,5 SD | 2 WSLH | ||
| Monocytes, count | Unclassified | Blood | 27,90% | 5 BV | |
| M-Protein Interpr. | Unclassified | Sebia Hydrasis LS | 90% consensus | 4 CAP | |
| MSAFP | Unclassified | Centaur | 3 SD | 4 CAP | |
| MShCG | Unclassified | Centaur | 3 SD | 4 CAP | |
| Mucinous carcinoma-associated antigen (M | Unclassified | Serum | 18,50% | 5 BV | |
| Myoglobin | Unclassified | 15 ng/mL or 30% | 6 AAB | ||
| Myoglobin | Unclassified | 30% | 8 CFX | ||
| Myoglobin | Unclassified | Serum | 19,60% | 5 BV | |
| Myoglobin - Qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
| Myoglobin - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
| N-Acetyl Glucosaminidase - Concentration | Unclassified | Urine | 53,10% | 5 BV | |
| N-Acetyl Glucosaminidase - Output | Unclassified | Urine | 46,50% | 5 BV | |
| N-Acetyl procainamide | Unclassified | +/- 15% | 3 NYS | ||
| N-Acetyl procainamide | Unclassified | Abbott AxSym | 25% | 4 CAP | |
| N-Acetyl procainamide | Unclassified | 20% | 8 CFX | ||
| Napa | Unclassified | Abbott AxSym | 25% | 4 CAP | |
| Neutrophyles, count | Unclassified | Blood | 22,40% | 5 BV | |
| Nitrogen - Output | Unclassified | Urine | 18,40% | 5 BV | |
| Noradrenaline | Unclassified | 50 nmol/day, 10% | 7 RCPA | ||
| Normetanephrine | Unclassified | 1,0 umol/day, 33% | 7 RCPA | ||
| Nortriptyline | Unclassified | 10 nmol/L, 10% | 7 RCPA | ||
| Nortriptyline | Unclassified | 15% | 8 CFX | ||
| NSE | Unclassified | 2,0 ug/L, 10% | 7 RCPA | ||
| N-Telopeptides | Unclassified | Urine | 80 nmolBCE/L, 10% | 7 RCPA | |
| Oestradiol | Unclassified | 100 pmol/L, 20% | 7 RCPA | ||
| Oestriol - Total | Unclassified | 20 nmol/L, 10% | 7 RCPA | ||
| Oestriol - Unconjugated | Unclassified | 5 nmol/L, 20% | 7 RCPA | ||
| Oligoclonal Bands | Unclassified | Sebia Hydrasis LS | 90% consensus | 4 CAP | |
| Opiates | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Opiates | Unclassified | Pos/Neg | 2 WSLH | ||
| Opiates | Unclassified | 20% or 2 SD | 3 NYS | ||
| Osmolality | Unclassified | Urine | 9. mOsm/kg or 10% | 6 AAB | |
| Osmolality | Unclassified | 8 mmol/kg | 7 RCPA | ||
| Osmolality | Unclassified | Freezing point | 2 SD | 4 CAP | |
| Osmolality | Unclassified | 3% | 8 CFX | ||
| Osmolality | Unclassified | Serum | 1,50% | 5 BV | |
| Osmolality | Unclassified | Urine | Freezing point | 3 SD | 4 CAP |
| Osmolality | Unclassified | Serum | 3 SD | 2 WSLH | |
| Osmolality | Unclassified | Urine | 3 SD | 2 WSLH | |
| Osmolality | Unclassified | Urine | 6 mmol/kg, 2% | 7 RCPA | |
| Osteocalcin | Unclassified | Serum | 11,20% | 5 BV | |
| Oxalate - Concentration | Unclassified | Urine | 48,20% | 5 BV | |
| Oxalate - Output | Unclassified | Urine | 46,80% | 5 BV | |
| Oxyhemoglobin | Unclassified | 3 SD | 2 WSLH | ||
| Oxyhemoglobin | Unclassified | Radiometer 725 | 4 CAP | ||
| PAP | Unclassified | 2,5 SD | 2 WSLH | ||
| Paracetamol | Unclassified | 20 umol/L, 10% | 7 RCPA | ||
| Partial thromboplastin time | Hematología | +/- 15% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| pCO2 | Unclassified | Radiometer 725 | 8% or 5 mm Hg (greater) | 4 CAP | |
| pCO2 | Unclassified | 5,0 mm Hg or 8% | 6 AAB | ||
| pCO2 | Unclassified | 5 kPa, 8% | 8 CFX | ||
| pCO2 | Unclassified | 2,0 mm Hg, 8% | 7 RCPA | ||
| pCO2 | Unclassified | Blood | 5,70% | 5 BV | |
| pH | Unclassified | Radiometer 725 | 4% | 4 CAP | |
| pH | Unclassified | 4% | 6 AAB | ||
| pH | Unclassified | 4% | 7 RCPA | ||
| pH | Unclassified | 4% | 8 CFX | ||
| pH [H+] | Unclassified | Blood | 3,90% | 5 BV | |
| pH - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
| pH,Fluid | Unclassified | Corning 445 pH meter | 4% | 4 CAP | |
| Phencyclidine | Unclassified | Pos/Neg | 2 WSLH | ||
| Phencyclidine | Unclassified | Abbott AxSym | 80% consensus | 4 CAP | |
| Phencyclidine | Unclassified | 20% or 2 SD | 3 NYS | ||
| Phenobarbital | Toxicología | +/- 20% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Phenobarbital | Toxicología | +/- 15% | 3 NYS | ||
| Phenobarbital | Toxicología | Abbott AxSym | 20% | 4 CAP | |
| Phenobarbital | Toxicología | 20% | 8 CFX | ||
| Phenobarbitone | Unclassified | 3,0 umol/L, 10% | 7 RCPA | ||
| Phenytoin | Toxicología | 3,0 umol/L, 10% | 7 RCPA | ||
| Phenytoin | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Phenytoin | Toxicología | +/- 15% | 3 NYS | ||
| Phenytoin | Toxicología | Abbott AxSym | 25% | 4 CAP | |
| Phenytoin | Toxicología | 25% | 8 CFX | ||
| Phenytoin - Free | Unclassified | TDX | 3 SD | 4 CAP | |
| Phosphate | Unclassified | 0,1 mmol/L, 10% | 7 RCPA | ||
| Phosphate | Unclassified | Serum | 10,20% | 5 BV | |
| Phosphate | Unclassified | Urine | 2,5 mmol/L | 7 RCPA | |
| Phosphate tubular reabsorption | Unclassified | Patient- | 3,30% | 5 BV | |
| Phosphate - Concentration | Unclassified | Urine | 31,10% | 5 BV | |
| Phosphate - Output | Unclassified | Urine | 22,10% | 5 BV | |
| Phospholipids | Unclassified | Serum | 8,60% | 5 BV | |
| Phosphorus | Unclassified | Urine | 3. mg/dL or 15% | 6 AAB | |
| Phosphorus | Unclassified | AU640 | 10,7% or 0,3 mg/dL (greater) | 4 CAP | |
| Phosphorus | Unclassified | 0,5 mg/dL or 12% | 2 WSLH | ||
| Phosphorus | Unclassified | 0,4 mg/dL or 15% | 6 AAB | ||
| Phosphorus | Unclassified | +/- 0,45 mg/dL or 13% | 3 NYS | ||
| Phosphorus | Unclassified | 12% | 8 CFX | ||
| Phosphorus | Unclassified | Urine | 0,5 mg/dL or 12% | 2 WSLH | |
| Phosphorus | Unclassified | Urine | AU640 | 23% | 4 CAP |
| Plasma Renin Activity | Unclassified | 1,0 ng/mL/hr, 25% | 7 RCPA | ||
| Plasma Total Porphyrin | Unclassified | 3 nmol/L, 15% | 7 RCPA | ||
| Platelet count | Hematología | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Platelet, count | Unclassified | Blood | 13,40% | 5 BV | |
| Platelets | Unclassified | 25% | 6 AAB | ||
| pO2 | Unclassified | 5 mm Hg, 5% | 7 RCPA | ||
| pO2 | Unclassified | 3SD | 6 AAB | ||
| pO2 | Unclassified | Radiometer 725 | 3 SD | 4 CAP | |
| pO2 | Unclassified | 2 SD | 8 CFX | ||
| Polylysine | Unclassified | 45 mmol/L or 30% | 6 AAB | ||
| Potassium | Química | Radiometer 725 | 0,5 mmol/L | 4 CAP | |
| Potassium | Química | 0,2 mmol/L | 7 RCPA | ||
| Potassium | Química | +/- 0,5 mmol/L | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Potassium | Química | Blood-Leukocyte | 16% | 5 BV | |
| Potassium | Química | 6% | 8 CFX | ||
| Potassium | Química | Serum | 5,80% | 5 BV | |
| Potassium | Unclassified | AU640 | 0,5 mmol/L | 4 CAP | |
| Potassium | Unclassified | Urine | 2 SD | 2 WSLH | |
| Potassium | Unclassified | Urine | AU640 | 29% | 4 CAP |
| Potassium | Unclassified | Urine | 2,0 mmol/L, 10% | 7 RCPA | |
| Potassium - Concentration | Unclassified | Urine | 31,30% | 5 BV | |
| Potassium - Output | Unclassified | Urine | 28,40% | 5 BV | |
| Potassium - POCT | Unclassified | POCT | 2,0 mmol/L | 7 RCPA | |
| Prealbumin | Unclassified | BNII | 25% or 5 mg/dL (greater) | 4 CAP | |
| Prealbumin | Unclassified | Serum | 14,50% | 5 BV | |
| Prealbumin | Unclassified | 2,5 SD | 2 WSLH | ||
| Pregnancy | Unclassified | Serum | pos/neg | 6 AAB | |
| Primidone | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Primidone | Toxicología | +/- 15% | 3 NYS | ||
| Primidone | Toxicología | 15% | 8 CFX | ||
| Procainamide | Unclassified | +/- 15% | 3 NYS | ||
| Procainamide | Unclassified | Abbott AxSym | 25% | 4 CAP | |
| Procainamide | Unclassified | 25% | 6 AAB | ||
| Procainamide | Unclassified | 20% | 8 CFX | ||
| Procainamide (and metabolite) | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Procainamide, N-Acetyl (NAPA) | Unclassified | 25% | 6 AAB | ||
| Procollagen type 1 N-terminal | Unclassified | Serum | 10,50% | 5 BV | |
| Progesterone | Unclassified | 300 pg/mL or 30% | 2 WSLH | ||
| Progesterone | Unclassified | Centaur | 3 SD | 4 CAP | |
| Progesterone | Unclassified | 2 SD | 8 CFX | ||
| Progesterone | Unclassified | 2 nmol/L, 25% | 7 RCPA | ||
| Progesterone | Unclassified | 0,3 ng/mL or 30% | 6 AAB | ||
| Progesterone | Unclassified | +/-25% or 1,0 ng/mL | 3 NYS | ||
| Prolactin | Unclassified | 3,6 ng/mL or 30% | 2 WSLH | ||
| Prolactin | Unclassified | 3,6 ng/mL or 30% | 6 AAB | ||
| Prolactin | Unclassified | Centaur | 3 SD | 4 CAP | |
| Prolactin | Unclassified | 20 mU/L, 20% | 7 RCPA | ||
| Prolactin | Unclassified | 2 SD | 8 CFX | ||
| Prolactin | Unclassified | +/-25% or 1,0 ug/L | 3 NYS | ||
| Prolactin (men) | Unclassified | Serum | 21,10% | 5 BV | |
| Prolyl endopeptidase | Unclassified | Plasma | 19,30% | 5 BV | |
| Propoxyphene | Unclassified | Pos/Neg | 2 WSLH | ||
| Propoxyphene | Unclassified | 20% or 2 SD | 3 NYS | ||
| Prostatic Specific Antigen (PSA) | Unclassified | 0,9 ng/mL or 30% | 6 AAB | ||
| Prostatic Specific Antigen (PSA) | Unclassified | Serum | 30% | 5 BV | |
| Protein | Unclassified | 10% | 2 WSLH | ||
| Protein - Total | Unclassified | 6% | 8 CFX | ||
| Protein - Total | Unclassified | 5,0 g/L | 7 RCPA | ||
| Protein - Total | Unclassified | AU640 | 10% | 4 CAP | |
| Protein - Total | Unclassified | Serum | 3,40% | 5 BV | |
| Protein - Total | Unclassified | Urine | 80% Agreement | 3 NYS | |
| Protein - Total | Unclassified | Urine | 10% | 2 WSLH | |
| Protein C | Unclassified | Serum | 18,70% | 5 BV | |
| Protein Electrophoresis Interpretation | Unclassified | Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
| Protein Electrophoresis Interpretation | Unclassified | Serum | Sebia Hydrasis LS | 90% consensus | 4 CAP |
| Protein Electrophoresis Interpretation (24 Hour) | Unclassified | Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
| Protein S | Unclassified | Plasma | 20,70% | 5 BV | |
| Protein - Concentration | Unclassified | Urine | 43,50% | 5 BV | |
| Protein- Output | Unclassified | Urine | 40% | 5 BV | |
| Prothrombin Time | Hematología | +/- 15% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Prothrombin Time | Hematología | Plasma | 5,30% | 5 BV | |
| Prothrombin Time | Unclassified | CoaguChek | 15% | 6 AAB | |
| Prothrombin Time | Unclassified | 15% | 6 AAB | ||
| Prothrombin Time | Unclassified | Whole Blood | 15% | 6 AAB | |
| PSA | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
| PSA | Unclassified | 0,9 ng/mL or 30% | 2 WSLH | ||
| PSA | Unclassified | +/- 3 SD | 3 NYS | ||
| PSA - Free | Unclassified | 0,9 ng/mL or 30% | 2 WSLH | ||
| PTH | Unclassified | Centaur | 3 SD | 4 CAP | |
| PTH | Unclassified | 2,5 pmol/L, 25% | 7 RCPA | ||
| Pyridinoline/creatinine, morning spot | Unclassified | Urine | 12,10% | 5 BV | |
| Pyruvate | Unclassified | Blood | 17,50% | 5 BV | |
| Qualitative hCG | Unclassified | Positive or Negative | 3 NYS | ||
| Quinidine | Toxicología | 2,0 umol/L, 10% | 7 RCPA | ||
| Quinidine | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Quinidine | Toxicología | +/- 15% | 3 NYS | ||
| Quinidine | Toxicología | Abbott AxSym | 25% | 4 CAP | |
| Quinidine | Toxicología | 25% | 8 CFX | ||
| RBC Folate | Unclassified | 2,5 SD | 2 WSLH | ||
| RBC Total Porphyrin | Unclassified | 0,3 umol/L rc, 15% | 7 RCPA | ||
| Red cell distribution wide | Unclassified | Blood | 4,60% | 5 BV | |
| Reticulocyte Count | Unclassified | 0,50% or 30% | 6 AAB | ||
| Reticulocyte highly fluorescent, count | Unclassified | Serum | 24% | 5 BV | |
| Reticulocyte low fluorescent, count | Unclassified | Serum | 2,60% | 5 BV | |
| Reticulocyte medium fluorescent, count | Unclassified | Serum | 19,60% | 5 BV | |
| Reticulocyte, count | Unclassified | Serum | 16,80% | 5 BV | |
| Reticulocytes | Unclassified | 3 SD | 2 WSLH | ||
| Retinol | Unclassified | Serum | 18,10% | 5 BV | |
| Rheumatoid Factor | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
| Rheumatoid Factor | Immunology | Serum | 13,50% | 5 BV | |
| Rheumatoid Factor | Unclassified | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
| Rheumatoid Factor | Unclassified | BNII | 2 SD | 4 CAP | |
| Rubella | Immunology | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
| Salicylates | Unclassified | 0,1 mmol/L, 10% | 7 RCPA | ||
| Salicylates | Unclassified | +/- 15% | 3 NYS | ||
| Salicylates | Unclassified | 25% | 2 WSLH | ||
| Salicylates | Unclassified | AU640 | 3 SD | 4 CAP | |
| Salicylates | Unclassified | 25% | 6 AAB | ||
| Salicylates | Unclassified | 20% | 8 CFX | ||
| SCC antigen | Unclassified | Serum | 45,80% | 5 BV | |
| Sedimentation Rate [ESR] | Unclassified | 2,5 SD | 2 WSLH | ||
| Selenium | Unclassified | Blood | 14,50% | 5 BV | |
| Selenium | Unclassified | Plasma | 14,50% | 5 BV | |
| Serotonin | Unclassified | 0,3 umol/day, 30% | 7 RCPA | ||
| Sex hormone binding globulin (SHBG) | Unclassified | Serum | 21,10% | 5 BV | |
| SHBG | Unclassified | 5 nmol/L, 10% | 7 RCPA | ||
| Sickle Cell Screen | Unclassified | Pos/Neg | 2 WSLH | ||
| Sodium | Química | 4 mmol/L, 5% | 8 CFX | ||
| Sodium | Química | Radiometer 725 | 4 mmol/L | 4 CAP | |
| Sodium | Química | AU640 | 4 mmol/L | 4 CAP | |
| Sodium | Química | 3,0 mmol/L | 7 RCPA | ||
| Sodium | Química | +/- 4 mmol/L | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Sodium | Química | Blood-Leukocyte | 0,577 | 5 BV | |
| Sodium | Química | Blood-Erythrocytes | 0,046 | 5 BV | |
| Sodium | Química | Serum | 0,009 | 5 BV | |
| Sodium | Unclassified | Urine | 2 SD | 2 WSLH | |
| Sodium | Unclassified | Urine | AU640 | 26% | 4 CAP |
| Sodium | Unclassified | Sweat | 2 mmol/L, 10% | 7 RCPA | |
| Sodium | Unclassified | Urine | 2,0 mmol/L, 10% | 7 RCPA | |
| Sodium - Concentration | Unclassified | Urine | 28,80% | 5 BV | |
| Sodium - Output | Unclassified | Urine | 32% | 5 BV | |
| Specific Gravity | Unclassified | Urine | 1% | 6 AAB | |
| Specific Gravity - Qualitative | Unclassified | Urine | 80% Agreement | 3 NYS | |
| Sperm Count | Unclassified | 3 million/mL or 25% | 6 AAB | ||
| Sperm Morphology | Unclassified | 5% normal or 20%% | 6 AAB | ||
| Sperm Viability | Unclassified | 5% viable or 20%% | 6 AAB | ||
| Superoxide dismutase | Unclassified | Serum | 19,10% | 5 BV | |
| Superoxide dismutase | Unclassified | Blood-Erythrocytes | 13,50% | 5 BV | |
| Sweat Conductivity | Unclassified | 2 mmol/L, 10% | 7 RCPA | ||
| T Uptake | Unclassified | 7% | 8 CFX | ||
| T3 uptake | Endocrinology | +/- 3 SD by method | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| T3 Uptake | Unclassified | Centaur | 3 SD | 4 CAP | |
| T3, T3 | Unclassified | Centaur | 3 SD | 4 CAP | |
| T3-uptake | Unclassified | Serum | 5,30% | 5 BV | |
| T4, Free | Unclassified | Centaur | 3 SD | 4 CAP | |
| T4, Total | Unclassified | Centaur | 20% or 1 ug/dL (greater) | 4 CAP | |
| Tacrolimus (FK 506) | Unclassified | IMX | 3 SD | 4 CAP | |
| Testosterone | Unclassified | Centaur | 3 SD | 4 CAP | |
| Testosterone | Unclassified | 2 SD | 8 CFX | ||
| Testosterone | Unclassified | 0,5 nmol/L, 20% | 7 RCPA | ||
| Testosterone | Unclassified | 0,3 ng/mL or 30% | 2 WSLH | ||
| Testosterone | Unclassified | 0,3 ng/mL or 30% | 6 AAB | ||
| Testosterone | Unclassified | +/-25% or 1,0 ng/dL | 3 NYS | ||
| Testosterone | Unclassified | Saliva | 22,70% | 5 BV | |
| Testosterone | Unclassified | Serum | 14% | 5 BV | |
| Testosterone - Free | Unclassified | 0,3 ng/mL or 30% | 2 WSLH | ||
| THC-cannabinoids | Unclassified | 20% or 2 SD | 3 NYS | ||
| Theophylline | Toxicología | 3,0 umol/L, 10% | 7 RCPA | ||
| Theophylline | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Theophylline | Toxicología | +/- 15% | 3 NYS | ||
| Theophylline | Toxicología | Abbott AxSym | 25% | 4 CAP | |
| Theophylline | Toxicología | 25% | 8 CFX | ||
| Thyroglobulin | Unclassified | Serum | 17,80% | 5 BV | |
| Thyroid Stimulating Hormone (TSH) | Endocrinology | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Thyroid Stimulating Hormone (TSH) | Unclassified | 3SD | 6 AAB | ||
| Thyroid Stimulating Hormone (TSH) | Unclassified | 30% | 8 CFX | ||
| Thyroid Stimulating Hormone (TSH) | Unclassified | Serum | 24,60% | 5 BV | |
| Thyroxin binding globulin (TBG) | Unclassified | Serum | 7,10% | 5 BV | |
| Thyroxine | Endocrinology | 8 nmol/L, 15% | 7 RCPA | ||
| Thyroxine | Endocrinology | +/- 20% or 1,0 mcg/dL (greater) | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Thyroxine - Free | Unclassified | 2 SD | 8 CFX | ||
| Thyroxine - Total | Unclassified | 8% | 8 CFX | ||
| Thyroxine (T4) | Unclassified | Serum | 8,30% | 5 BV | |
| Thyroxine - Free | Unclassified | 3SD | 6 AAB | ||
| Thyroxine - Total | Unclassified | 1,0 µg/dL or 20% | 6 AAB | ||
| TIBC | Unclassified | 10,0 umol/L | 7 RCPA | ||
| TIBC | Unclassified | Centaur | 20% | 4 CAP | |
| Tissue polypeptide antigen (TPA) | Unclassified | Serum | 36,10% | 5 BV | |
| Tissue polypeptide specific antigen (TPS) | Unclassified | Serum | 58,30% | 5 BV | |
| Tobramycin | Toxicología | 0,5 mg/L, 10% | 7 RCPA | ||
| Tobramycin | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Tobramycin | Toxicología | +/- 15% | 3 NYS | ||
| Tobramycin | Toxicología | Abbott AxSym | 25% | 4 CAP | |
| Tobramycin | Toxicología | 25% | 8 CFX | ||
| Total Beta hCG | Unclassified | +/- 3 SD | 3 NYS | ||
| Total Bilirubin, Neonatal | Unclassified | 15 umol/L, 10% | 7 RCPA | ||
| Total Carotenoids | Unclassified | 0,4 umol/L, 10% | 7 RCPA | ||
| Total catecolamines - Concentration, 24h | Unclassified | Urine | 29,80% | 5 BV | |
| Total Estriol | Unclassified | +/-25% or 3,0 ng/mL | 3 NYS | ||
| Total Glycated Hemoglobin | Unclassified | 1,2 or 20% | 2 WSLH | ||
| Total Iron Binding Capacity (TIBC) | Unclassified | 25% | 6 AAB | ||
| Total Protein | Química | +/- 10% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Total Protein | Unclassified | Urine | 1,0 mg/dL or 25% | 6 AAB | |
| Total Protein | Unclassified | 10% | 6 AAB | ||
| Total Protein | Unclassified | Urine | AU640 | 44% | 4 CAP |
| Total Protein | Unclassified | Cerebrospinal Fluid | 0,1 g/L, 10% | 7 RCPA | |
| Total Protein | Unclassified | Urine | 0,1 g/L, 10% | 7 RCPA | |
| Total PSA | Unclassified | 1,5 ug/L, 15% | 7 RCPA | ||
| Total T3 (Endocrinology) | Unclassified | 0,3 nmol/L, 20% | 7 RCPA | ||
| Total T3 (General Chemistry) | Unclassified | 0,3 nmol/L, 15% | 7 RCPA | ||
| Total T4 | Unclassified | 8 nmol/L, 15% | 7 RCPA | ||
| Transferrin | Unclassified | 2,5 SD | 2 WSLH | ||
| Transferrin | Unclassified | 0,5 g/L | 7 RCPA | ||
| Transferrin | Unclassified | BNII | 20% | 4 CAP | |
| Transferrin | Unclassified | 12% | 8 CFX | ||
| Transferrin | Unclassified | Serum | 3,80% | 5 BV | |
| Tricyclic Antidepressants | Unclassified | Pos/Neg | 2 WSLH | ||
| Tricyclic Antidepressants | Unclassified | 20% or 2 SD | 3 NYS | ||
| Tricyclic Antidepressants | Unclassified | 10 nmol/L, 10% | 7 RCPA | ||
| Tricyclic Antidepressants | Unclassified | 15% | 8 CFX | ||
| Triglycerides | Unclassified | 0,20 mmol/L, 10% | 7 RCPA | ||
| Triglycerides | Unclassified | Serum | 27,90% | 5 BV | |
| Triglycerides | Química | +/- 25% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Triglycerides | Química | AU640 | 25% | 4 CAP | |
| Triglycerides | Química | 15% | 8 CFX | ||
| Triiodothyronine | Endocrinology | +/- 3 SD | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Triiodothyronine - Free | Unclassified | 20% | 8 CFX | ||
| Triiodothyronine - Total | Unclassified | 20% | 8 CFX | ||
| Triiodothyronine (T3) | Unclassified | Serum | 11,40% | 5 BV | |
| Triiodothyronine, Free (Free T3) | Unclassified | 1,5 pg/mL or 30% | 6 AAB | ||
| Triiodothyronine, Total (T3) | Unclassified | 3SD | 6 AAB | ||
| Troponin I | Unclassified | Centaur | not evaluated | 4 CAP | |
| Troponin I | Unclassified | 2 SD | 8 CFX | ||
| Troponin I | Unclassified | 0,9 ng/mL or 30% | 6 AAB | ||
| Troponin I | Unclassified | 0,2 ng/mL, 10% | 7 RCPA | ||
| Troponin I - Qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
| Troponin I - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
| Troponin T | Unclassified | 2 SD | 8 CFX | ||
| Troponin T | Unclassified | 0,1 ng/mL, 10% | 7 RCPA | ||
| Troponin T | Unclassified | 0,1 ng/mL or 30% | 6 AAB | ||
| Troponin T - Qualitative | Unclassified | Pos/Neg | 2 WSLH | ||
| Troponin T - Quantitative | Unclassified | 2 SD | 2 WSLH | ||
| Thyroid Stimulating Hormone (TSH) | Unclassified | Centaur | 3 SD | 4 CAP | |
| Thyroid Stimulating Hormone (TSH) | Unclassified | 0,6 mU/L, 15% | 7 RCPA | ||
| Tumor Necrosis Factor-a | Unclassified | Serum | 48,40% | 5 BV | |
| TUptake | Unclassified | 3SD | 6 AAB | ||
| uE3 (Maternal Sera) | Unclassified | Maternal Sera | +/- 3 SD | 3 NYS | |
| Unsaturated Iron Binding Capacity (UIBC) | Unclassified | 25% | 6 AAB | ||
| Urate | Unclassified | 0,050 mmol/L | 7 RCPA | ||
| Urate | Unclassified | Serum | 11,90% | 5 BV | |
| Urate | Unclassified | Urine | 0,3 mmol/L | 7 RCPA | |
| Urate - Concentration, 24h | Unclassified | Urine | 28,70% | 5 BV | |
| Urate- Output, 24h | Unclassified | Urine | 21,10% | 5 BV | |
| Urea | Unclassified | AU640 | 9% or 2 mg N/dL (greater) | 4 CAP | |
| Urea | Unclassified | 0,1 mmol/L, 10% | 7 RCPA | ||
| Urea | Unclassified | Serum | 15,70% | 5 BV | |
| Urea | Unclassified | Urine | 20 mmol/L, 10% | 7 RCPA | |
| Urea | Unclassified | Urine | AU640 | 21% | 4 CAP |
| Urea Nitrogen | Química | +/- 2 mg/dL or +/- 9% (greater) | 1 CLIA | ||
| Urea Nitrogen | Unclassified | Urine | 2 mg/dL or 9% | 2 WSLH | |
| Urea - Concentration, 24h | Unclassified | Urine | 27,30% | 5 BV | |
| Urea - Output, 24h | Unclassified | Urine | 22,10% | 5 BV | |
| Urea/Urea Nitrogen | Unclassified | 16% | 8 CFX | ||
| Urea-POCT | Unclassified | POCT | 1,0 mmol/L, 10% | 7 RCPA | |
| Uric Acid | Química | +/- 17% | 1 CLIA, 2 WSLH, 3 NYS, 6 AAB | ||
| Uric Acid | Unclassified | Urine | 17% | 6 AAB | |
| Uric Acid | Unclassified | 17% | 6 AAB | ||
| Uric Acid | Unclassified | 12% | 8 CFX | ||
| Uric Acid | Unclassified | Urine | 17% | 2 WSLH | |
| Uric Acid | Unclassified | Urine | AU640 | 24% | 4 CAP |
| Uric Acid | Química | AU640 | 17% | 4 CAP | |
| Urine ALA | Unclassified | 5 umol/L, 25% | 7 RCPA | ||
| Urine Porphobilinogen - Quantitative | Unclassified | 5 umol/L, 20% | 7 RCPA | ||
| Urine Total Porphyrin | Unclassified | 15 nmol/L, 15% | 7 RCPA | ||
| Valproate | Unclassified | 25 umol/L, 10% | 7 RCPA | ||
| Valproic Acid | Toxicología | +/- 25% | 1 CLIA, 2 WSLH, 6 AAB | ||
| Valproic Acid | Toxicología | +/- 15% | 3 NYS | ||
| Valproic Acid | Unclassified | Abbott AxSym | 25% | 4 CAP | |
| Valproic Acid | Unclassified | 25% | 6 AAB | ||
| Valproic Acid | Unclassified | 15% | 8 CFX | ||
| Valproic Acid, free | Unclassified | TDX | 3 SD | 4 CAP | |
| Vancomycin | Unclassified | Abbott AxSym | 3 SD | 4 CAP | |
| Vancomycin | Unclassified | 2,0 mg/L, 10% | 7 RCPA | ||
| Vancomycin | Unclassified | 1,5 ug/mL or 25% | 6 AAB | ||
| Vancomycin | Unclassified | +/- 15% | 3 NYS | ||
| Vancomycin | Unclassified | 25% | 2 WSLH | ||
| Vancomycin | Unclassified | 20% | 8 CFX | ||
| Vanilmandelic Acid concentration, 24h | Unclassified | Urine | 31,30% | 5 BV | |
| Vitamin A | Unclassified | 0,3 umol/L, 10% | 7 RCPA | ||
| Vitamin B-12 | Unclassified | 60 pg/mL or 30% | 2 WSLH | ||
| Vitamin B-12 | Unclassified | 60 pg/mL or 30% | 6 AAB | ||
| Vitamin B-12 | Unclassified | 20 pmol/L, 20% | 7 RCPA | ||
| Vitamin B-12 | Unclassified | +/- 25% | 3 NYS | ||
| Vitamin B-12 | Unclassified | Centaur | 3 SD | 4 CAP | |
| Vitamin D3 | Unclassified | 5 nmol/L, 15 | 7 RCPA | ||
| Vitamin E | Unclassified | 5,0 umol/L, 10% | 7 RCPA | ||
| Von Willebrand factor | Unclassified | Plasma | 7,40% | 5 BV | |
| Water | Unclassified | Serum | 3,30% | 5 BV | |
| White cell differentiation | Hematología | Target +/- 3 SD based on percentage of different types of white cells | 1 CLIA, 2 WSLH | ||
| Zinc | Unclassified | Serum | 13,50% | 5 BV | |
| Zinc | Unclassified | Plasma | 11% | 5 BV | |
| ZPP | Unclassified | +/-15% (µmol/mol heme) | 3 NYS |
Abbreviations and Sources
| Abbreviation | Source |
|---|---|
| 1 CLIA | CLIA ’88, CLIA |
| 2 WLSH | Wisconsin State Laboratory of Hygiene |
| 3 NYS | Wadsworth Center of the New York State Department of Health |
| 4 CAP | College of American Pathologists (CAP) |
| 5 BV | 2004 update of the Spanish Society of Clinical Chemistry and Molecular Pathology (SEQC) table of Desirable Quality Specifications based on Biological Variation. |
| 6 AAB | American Association of Bioanalysts (AAB) |
| 7 RCPA | The Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist association Quality Assurance Program |
| 8 CFX | Canadian Fixed limits from the College of Physicians and Surgeons of Saskatchewan |
